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Nanomedicine, a branch of nanotechnology which includes the use of nanoparticles, is set to 
revolutionize the area of gene therapy. Gold nanoparticles (AuNPs) have steadily gained 
favour as promising gene and drug delivery agents in clinical medicine for diagnostics and 
the treatment of diseases such as cancer. Cancer is a chronic disease with mortality rates 
increasing steadily. It has been highlighted as a genetic disease with a rising need for the 
development of innovative gene therapy strategies and, thus, the development of safe and 
effective gene delivery vehicles. AuNPs feature unique properties which includes small size, 
high dispersity, stability and surface plasmon resonance with a capacity for ease-of-synthesis 
and parametric control via chemical methods. Characteristics which favour gene delivery 
include their biocompatibility, voluntary cellular uptake and low core toxicity. 
Functionalisation with cationic polymers enhances the properties of AuNPs in terms of 
condensation of nucleic acids, cellular internalisation, protection against nucleases and 
release of the therapeutic gene for expression. Over the years, gene therapy applications have 
routinely utilized therapeutic plasmid DNA (pDNA) for treatment. However, pDNA 
expression is associated with many limitations hindering cellular trafficking and nuclear 
entry. As a promising alternative, mRNA molecules overcome these intracellular barriers 
with no risk of insertional mutagenesis. In this study, the unique properties of AuNPs, 
cationic polymers and mRNA molecules were exploited and optimized to provide effective 
gene delivery vehicles for the intracellular release of mRNA for future cancer gene therapy 
applications, an area of research which until recently has not been investigated. AuNPs were 
synthesized and functionalised with chitosan (CS) and poly-l-lysine (PLL), respectively. All 
nanoparticles and their nanocomplexes were characterized using UV-vis spectrophotometry, 
ICP, FTIR, transmission electron microscopy (TEM) and Nanoparticle tracking analysis 
(NTA). Functionalised AuNP:Fluc-mRNA binding, compaction and nuclease protection were 
assessed using the gel retardation, dye displacement and  nuclease protection assays, 
respectively. The effects of these nanocomplexes in vitro were assessed on three human cell 
lines, embryonic kidney (HEK293), colorectal adenocarcinoma (Caco-2) and breast 
adenocarcinoma (MCF-7). The cytotoxicity profile of the nanocomplexes was evaluated 
using the MTT assay and mRNA transfection efficiency assessed using the luciferase reporter 
gene assay in the three human cell lines. The AO/EB apoptosis assay was employed to 
confirm the mechanism of cell death as being either apoptotic or necrotic.  
iii 
 
Results show that both functionalised nanocomplexes exhibit suitable and favourable 
properties such as small size (CS-AuNP nanocomplex: 95.0 nm and PLL-AuNP 
nanocomplex: 89.4 nm), colloidal stability (zeta potential: CS-AuNP nanocomplex: 25.9 mV 
and PLL-AuNP nanocomplex: -97.1 mV), efficient binding and protection against nucleases, 
low cytotoxicity (<40%) and significant transgene expression. Furthermore, these 
functionalised nanocomplexes exhibited apoptosis induction selective to cancer cells when 
compared to the non-cancer cell line. Functionalised AuNPs proved to be more efficient than 
their respective cationic polymers by themselves, indicating that AuNPs improve cationic 
polymer properties and functions.  Overall, these characteristics highlight the potential of 
these AuNPs as suitable carriers of mRNA in vitro and with further studies can be extended 
to biomedical applications, especially in cancer and immuno-therapy. 
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Cancer is a leading global health concern, claiming more than 8 million deaths annually 
which is expected to rise to 23.6 million deaths by 2030 (International Agency for Research 
on Cancer and World Health Organization, 2014). The basic hallmark of cancer is 
uncontrolled cell proliferation which is coupled with invasion and metastasis, induction of 
angiogenesis, resistance to apoptosis, altered differentiation, self-sufficient in-growth signals, 
resistance to anti-growth factors and secretion of growth factor molecules (Hanahan and 
Weinberg, 2011). These molecular mechanisms render many of the conventional cancer 
treatments such as chemotherapy and radiotherapy inefficient due to a lack of target cell 
specificity, multi-drug resistance, poor drug penetration and unpleasant side-effects (Pedrosa 
et al., 2015). The pathophysiological and genetic processes contributing to cancer cell 
transformation and tumorigenesis require much investigation and the development of novel 
innovative cancer treatment strategies is crucial. 
Gene therapy is the delivery of therapeutic nucleic acids for the treatment of genetic diseases 
including cancer (Shan et al., 2012). The challenge facing gene therapy is the development of 
an ideal gene delivery system which can safely, efficiently and selectively deliver the nucleic 
acid cargo to the intended cells (Verma et al., 2014), in addition to overcoming the various 
intracellular barriers encountered (Elsabahy et al., 2011). The use of non-viral delivery 
systems has gained favour due to their unlimited clone capacity, low immunogenicity, low 
cytotoxicity and ability for repeated application, in comparison to viral methods (Gardlík et 
al., 2005). 
Inorganic nanoparticles have recently emerged as attractive nanocarriers in comparison to the 
traditional lipid-based vectors due to their numerous advantages such as tuneable size and 
surface properties, multifunctional capabilities and the capacity to translate the metal core’s 
physical properties to the delivery vehicle (Ding et al., 2014). In particular, gold 
nanoparticles (AuNPs) provide a suitable platform for the development of efficient gene 
delivery vehicles due to characteristics such as their inert core, small size, colloidal stability, 
high dispersity and surface plasmon resonance. AuNPs possess a high surface-to-volume 
ratio which allows for facile modification with various functional moieties such as cationic 
2 
 
polymers which include chitosan and poly-l-lysine, thus controlling their reactivity, degree of 
toxicity and cellular uptake (Sivaramakrishnan et al., 2014).  
These cationic polymer functionalised AuNPs possess additional advantages such as low 
toxicity, biodegradability, bio-adhesiveness ensuring localized concentration of nucleic acid 
molecules via electrostatic interactions, protection against nuclease degradation, possibility of 
receptor-mediated endocytosis and release of the therapeutic cargo via the “proton-sponge 
effect” (Pedrosa et al., 2015). 
To date, plasmid DNA (pDNA) has been commonly used in gene therapy strategies. 
However, the use of pDNA faces many challenges such as the requirement for transportation 
across the nuclear membrane, cell-cycle dependency and the use of large quantities to elicit 
gene expression. This has been identified as a rate-limiting step in gene transfection (Ding et 
al., 2014). In addition, pDNA carries the risk of insertional mutagenesis and induction of 
immune responses due to their viral promoter components. In comparison, mRNA is able to 
overcome these endosomal barriers, does not require nuclear uptake, produces rapid gene 
expression as protein translation occurs within the cytoplasm, has no risk of insertional 
mutagenesis, is cell-cycle independent and is suitable for hard-to-transfect-cells (Matsui et 
al., 2015).  
This study is novel in that it exploits the unique properties of cationic polymer functionalised 
AuNPs as delivery vehicles for mRNA molecules encompassing a luciferase gene (Fluc-
mRNA) to investigate gene delivery and expression in three mammalian cell lines. This study 
will serve to provide a platform for determining the feasibility of these mRNA 
nanocomplexes in future genetic vaccination and immunotherapy in cancer treatment, an area 
of research which until recently has not been fully investigated. 
 
1.1 Aim and objectives  
This study aims to design, synthesize, functionalise and fully characterize the AuNPs, 
functionalised AuNPs and their nanocomplexes with Fluc-mRNA. Functionalisation of 
AuNPs will be carried out using the cationic polymers, chitosan and poly-l-lysine. 
Furthermore, their cytotoxicity, transgene expression and apoptosis induction will be 
examined on selected mammalian cell lines in vitro.   
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The main objectives will include: 
1. To synthesize AuNPs using the sodium citrate reduction method.  
2. To functionalise AuNPs with chitosan (CS) and poly-l-lysine (PLL). 
3. To fully characterize the synthesized AuNPs, functionalised AuNPs and 
nanocomplexes. 
4. To assess the binding and protection ability of the functionalised AuNPs, CS and PLL 
to Fluc-mRNA using the gel retardation, dye displacement and nuclease protection 
assays.  
5. To finally investigate the biological activity of these nanocomplexes with regards to 
cytotoxicity using the MTT assay gene expression using the Luciferase reporter gene 
assay, and apoptosis induction using the acridine orange-ethidium bromide (AO/EB) 
dual staining method in vitro. 
 
1.2 Outline of thesis 
This thesis is written in the format of two research papers and is divided into five chapters.  
Chapter 1 includes a basic introduction highlighting the need for this research, together with 
the aim and objectives of the study.  
Chapter 2 provides a detailed and up to date review of literature and contextual information 
on the various areas of interest in this study, including cancer, gene therapy, cationic 
polymers and AuNPs.  
Chapter 3 is presented in the format of a research paper which includes a brief introduction, 
methods and materials, results, discussion and a conclusion. The title of the paper is 
‘Chitosan functionalised gold nanoparticle mediated delivery of Fluc-mRNA in vitro: 
synthesis, characterization, cytotoxicity and transfection efficiency.’  
Chapter 4 is also presented in the format of a research paper which includes a brief 
introduction, methods and materials, results, discussion and a conclusion. The title of the 
paper is ‘Poly-l-lysine functionalised gold nanoparticle mediated delivery of Fluc-mRNA in 
vitro: synthesis, characterization, cytotoxicity and transfection efficiency.’  
Chapter 5 provides the concluding remarks, summarizing and highlighting the results 
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The global health impact of cancer has been a continuous cause for concern with mortality 
rates increasing steadily every year. Despite the extensive progress in research and 
development of many treatment strategies including surgery, hormone therapy, chemotherapy 
and radiotherapy, numerous side effects such as risk of toxicity and non-specificity (Deb et 
al., 2011) persist, reducing their effectiveness. In this regard, the complexity and 
heterogeneity of cancer have contributed to the difficulty of developing a single effective 
therapeutic solution. However, the knowledge of the genetics and molecular biology 
associated with the development of cancer has expanded tremendously over the past few 
decades and can now be exploited in the search of an effective treatment to eradicate the 
burden of this disease.  
 
2.1.1 The burden of cancer, causes and risk factors 
The burden and incidence of cancer is alarmingly high and is predicted to increase 
substantially on a global scale in the next few years.  Of all diagnosed cases, 40% were 
associated with lung, breast, colorectal and stomach cancer, with 34.2% of reported lung 
cancer cases occurring in men and 43.3% of women being diagnosed with breast cancer. 
Developing countries which includes South Africa, account for more than 70% of all reported 
cancer-associated deaths with a 15% rise predicted by 2050 (Bray and Møller, 2006).  
In South Africa, the commonly occurring cancers include breast, lung, oesophageal, 
colorectal, liver, prostate, cervical, lymphoma, oral, pancreatic, skin, bladder, stomach and 
leukaemia (Cancer Association of South Africa, 2016). Cancer can be caused by several risk 
factors or a combination thereof, including age, sex, environment, lifestyle, dietary choices, 
physical inactivity, genetics, carcinogens, physical agents, weak immune systems, infections 





Figure 2.1: Cancer-causing factors and their related incidences worldwide (Cantley et al., 2012). 
 
2.1.2 The development and genetics of cancer 
The development of cancer is associated with many abnormalities such as the uncontrolled 
proliferation of cancer cells and the lack of response to multiple normal regulatory growth 
signals leading to the formation of masses or tumours. These abnormalities are reflected in 
their properties and behaviour which distinguishes them from normal cells (Figure 2.2). 
Ultimately, cancer cells invade normal cells and spread throughout the body to other tissues 
and organs in a process termed metastasis. Malignant tumours formed secrete hormones to 
induce the formation of new blood vessels which invade the tissues of the tumour by means 
of capillary buds and sprouts in a process termed angiogenesis (Adair and Montani, 2010), 
providing a continuous blood supply for nourishment and growth.  
The understanding of the underlying genetic mechanisms and their roles in cancer 
development are crucial in the designing of suitable therapeutic strategies. A balance between 
cell proliferation and programmed cell death (apoptosis) has to be maintained to ensure tissue 
and organ integrity and functionality. Mutations of cellular genetic elements are indicated as 
one of the causes of cancer development (Lodish et al., 2000). The inheritance of a genetic 




Figure 2.2: Morphological differences between normal and cancer cells (Fadjari, 2011). In 
comparison to normal cells, cancer cells grow and divide at an abnormally rapid rate, poorly 
differentiate, possess abnormal membranes, cytoskeletal proteins and various other morphological 
characteristics. 
 
The multi-hit model theory states that a substantial number of different gene mutations give 
rise to the transformation of normal cells to cancer cells (Chial, 2008). Mutations of cell 
division, cell death and DNA repair genes have been implicated in the loss of cell 
proliferation control. Hence, cancer can be considered as a genetic disease due to the 
accumulation of genetic mutations that affect normal cellular processes. To date, more than 
100 different genes and their gene products have been identified in promoting carcinogenesis 
(Fogar et al., 2005). These genes can be proto-oncogenes that become activated or tumour 
suppressor genes that are inactivated, giving rise to the development of cancer. 
Common genetic alterations that occur are point mutations, gene amplification and 
chromosomal rearrangements which alter the encoded amino acid sequence for a specific 
protein (Pelengaris, 2013). Conventional therapies using drugs treat the symptoms of cancer 
but do not eliminate the underlying genetic causes leading to limited efficacy often due to  
multidrug resistance, poor drug penetration into tumours and damage to normal tissues 
(Ashworth et al., 2011). The use of gene therapy has emerged as a promising strategy for the 
treatment of the underlying genetic mutations in cancer development. 
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2.2 Gene therapy 
Gene therapy, the use of nucleic acids as therapeutic agents in the hope of curing human 
diseases, was initially devised as a strategy to treat monogenic inherited diseases but has 
since expanded to include other diseases such as cancer (Gardlík et al., 2005). The 
therapeutic gene, also known as a  transgene, is designed to augment, suppress or repair the 
defective gene (Ramamoorth and Narvekar, 2015). Nucleic acids are limited by size and 
physiochemical properties in the sense that they cannot diffuse directly through to the plasma 
membrane, thus giving rise to the development of delivery strategies and vehicles to 
overcome these limitations. The therapeutic gene is loaded onto a delivery vehicle or vector 
which transports the gene to the target cell.  
The challenge facing gene therapy is for the gene to be successfully transferred into the target 
cell through the cytoplasm and into the nucleus, transcribed into mRNA and translated into a 
protein to induce its therapeutic effect (Rivera-Gil et al., 2012). The optimal vector and 
method of delivery are designed based on the type of target cells, their characteristics, 
expression, duration and the size of the therapeutic gene to be transported (Ramamoorth and 
Narvekar, 2015). Therefore, the choice of vector and delivery method is a critical step in 
achieving gene delivery. In addition, vectors are required to carry genetic material into the 
cells due to their sensitivity to nuclease degradation, hydrophilic poly-anionic nature and 
large size that limit passive penetration of the cell membrane (Ibraheem et al., 2014). There 
are two broad classes of gene delivery methods, viz. viral and non-viral methods. 
 
2.2.1 Viral gene delivery methods 
Viral vectors such as the retrovirus, lentivirus, herpes simplex virus, adenovirus and adeno-
associated virus have been used in more than 70% of human clinical trials to date (Cotrim 
and  Baum, 2008). A brief description of some of the commonly used viral vectors, their 
advantages and disadvantages and nucleic acid loading capacity are provided in Table 2.1. 
Viral vectors have the natural tendency to enter cells through receptor-mediated endocytosis 
and initiate expression of their own proteins using the cells biosynthetic machinery due to 
their strong promoters (Lundstrom and Boulikas, 2003). Thus, their rate of transfection is 




Table 2.1. Examples of viral vectors, properties, advantages and disadvantages adapted from 
(Bolhassani and Rafati, 2011; Lundstrom and Boulikas, 2003; Ponder, 2001). 
Virus Description Loading 
capacity 
Advantages  Disadvantages 
Adenovirus Non-enveloped, 
icosahedral-shaped, 
linear dsDNA genome 
High  
(36 kb) 






production of high 
titres 
Insertional mutagenesis, 
slow transient expression, 
strong immunogenicity, 






linear dsDNA genome 
Medium 
(7.5 kb) 










immunity in humans 
Herpesvirus Enveloped, spherical-
shaped, linear dsDNA 
genome. Example: 









Cytotoxicity in various 
cells 








expression, high titre 
production. 
Restricted host range, 
insertional mutagenesis, 
transfection of dividing 
cells only 
















The use of viral vectors raises many health concerns such as immune responses, toxicity, 
inflammatory responses, degeneration of tissues, toxin production and insertional 
mutagenesis which may disrupt the expression of tumour suppression genes or activate 
oncogenes leading to the formation of malignant tumours. In addition, these vectors are only 
able to carry small sequences of nucleic acid in their genome, making large-scale production 
difficult. They are difficult to construct and some viruses require the use of a helper virus. 
Due to these reasons, researchers have had to study and develop alternative methods such as 
non-viral gene delivery. 
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2.2.2  Non-viral gene delivery methods 
Non-viral methods include the physical and chemical based delivery methods. Non-viral 
methods possesses many advantages over viral methods such as unlimited clone capacity, 
low immunogenicity, low cytotoxicity and the ability of repeated application (Gardlík et al., 
2005). Some of these methods are briefly discussed below. 
 
2.2.2.1 Physical methods 
Physical methods allow for the direct penetration of genes into the cytosol by fine needle 
punctures, electric impulses or high-pressure gas, thereby avoiding all the limitations 
associated with viral and chemical methods. Direct injection of nucleic acids into tissues is 
the simplest method of gene therapy to date (Mansouri et al., 2004) but gene expression is 
much lower than viral or liposomal vectors. Naked nucleic acid delivery is faced with 
challenges such as degradation by serum nucleases and clearance by the mononuclear 
phagocyte systems (MPS), reducing their gene transfection efficiency (Gascón et al., 2013). 
Hence, this method is limited to injection to accessible tissues such as the muscle, skin, 
cardiac muscle, liver and solid tumours (Ramamoorth and Narvekar, 2015). 
Particle bombardment/ gene gun method involves the coating of nucleic acids onto metal 
micro-particles such as gold or tungsten which are then fired at high velocity into tissues or 
cells through a perforated plate using a ballistic gun. This method has been used to transfer 
therapeutic genes with transient expression to mammalian cells in vitro and in vivo (Ibraheem 
et al., 2014). Advantages include safety, simplicity and the ability of crossing physical 
barriers such as the skin and muscle layer. Disadvantages include inefficiency of gene 
transfer, low stability of the nucleic acid and damage to cells.  
Electroporation exploits the electrical conductivity and the permeability properties of a cell 
membrane which can be altered by the application of a high voltage external electric field. 
(Ramamoorth and Narvekar, 2015). Pores are formed in the cell membrane through which 
exogenous molecules such as nucleic acids are taken up by the cells. The high cell death, 
inability to access large portions of tissue and the implantation of electrodes into internal 
organs have limited the use of this method. The transfection efficiency is dependent on both 
physical and biological properties such as field intensity, pulse duration, electrode geometry, 
size, shape and density of cells (Ibraheem et al., 2014). 
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Sonoporation, an extension from electroporation results in acoustic cavitations induced by 
the ultrasound frequencies that disrupt and permeate the cell membrane allowing nucleic 
acids to be delivered into cells (Ibraheem et al., 2014). This method is non-invasive and site-
specific. Therapeutic genes are commonly incorporated into a microbubble, administered 
systemically and, thereafter, the application of ultrasound is conducted allowing for the 
deposition of the transgene. Microbubbles consist of a biocompatible outer shell and a gas 
filled core (nitrogen or air) conjugated with sulphur hexafluoride and perfluorocarbon to 
obtain a high molecular weight (Ramamoorth and Narvekar, 2015). This method is dependent 
on the frequency, time of ultrasound, the use of a contrast factor, size and the concentration 
of the nucleic acid.  
Magnetofection is a process involving the use of magnetic particles complexed with nucleic 
acids brought into contact with the cell monolayer by placing a magnet under the tissue 
culture dish or they are introduced intravenously and brought towards the target using high 
gradient external magnets. The magnetic field gradient generated increases sedimentation of 
these complexes and increases transfection speed (Ramamoorth and Narvekar, 2015). The 
therapeutic gene is released by charge interaction, enzymatic cleavage of cross linking 
molecules or degradation in the matrix. This method has been successfully applied to a 
variety of cell lines, primary and hard-to-transfect cell lines (Nayerossadat et al., 2012). 
 
2.2.2.2 Chemical methods 
Chemical based gene delivery vectors have the potential to overcome the limitations 
associated with viral and physical methods. Gene transfection efficiency and cytotoxicity can 
be controlled by manipulating their physical and chemical properties such as size, surface 
composition and surface potential. These vectors can interact with nucleic acids to form 
nano-sized conjugates suitable for transport through the cell membrane. The most popular 
chemical based gene delivery systems are discussed briefly below. 
Liposomes are vesicles made up of synthetic lipid bilayers, closely resembling the structure 
of biological membranes. These vesicles spontaneously self-assemble upon dispersal of the 
lipids into aqueous solutions (Ibraheem et al., 2014). Liposomes can be anionic, neutral or 
cationic. The former two require entrapment of the macromolecule while cationic liposomes 
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can spontaneously interact with negatively charged nucleic acids to form ‘lipoplexes’ 
(Wheeler et al., 1999).  
Cationic liposomes can also favourably interact with the negatively charged cell membrane 
via electrostatic binding, allowing for fusion and direct delivery of the nucleic acid across the 
plasma membrane (Zelphati et al., 2001). Advantages associated with cationic liposomes are 
ease of preparation, biocompatibility, low immunogenicity, transfection of many cell types 
and high nucleic acid loading capacity. Disadvantages include cytotoxicity in vivo, 
requirement of helper lipids, non-specific interactions with serum proteins and enzymes, 
decreased cell adhesion, haemolysis and low transfection compared to viral vectors 
(Mansouri et al., 2004). 
Cationic polymers (CPs), comprising natural or synthetic polymers are regarded as being 
stable and better able to condense nucleic acids than cationic liposomes. Natural polymers 
include chitosan, pol-l-lysine, gelatin, sodium alginate and albumin. Synthetic CPs include 
polyethyleneimine, polyethylene glycol, poly-lactide co-glycolides and poly-glutamic acid. 
CPs possess characteristics such as structural variability, versatility, efficient binding of 
therapeutic molecules without comprising their function, biodegradability, low cytotoxicity, 
efficient nucleic acid release and the ability to elicit long-term expression without insertional 
oncogenesis (Nayerossadat et al., 2012). The size and charge density of these vectors 
determine their transfection efficiency, the longer the cationic polymer chain the higher the 
condensation of nucleic acids and their protection against nuclease degradation (Gardlík et 




Chitosan belongs to a family of linear polysaccharides comprising β (1-4) linked units of N-
acetyl glucosamine (N-acetyl-2-amino-2-deoxy-D-glucose) and glucosamine (2-amino-2-
deoxy-D-glucose) and is commonly used in gene and drug delivery. It is derived from the 
deacetylation of chitin, found in crustacean shells, fungi and bacteria (Andersen et al., 2015). 
The degree of deacetylation determines the biodegradability, biocompatibility, cytotoxicity, 
viscosity, crystallinity and solubility of chitosan (Hsu et al., 2011). Chitosan is readily 
degraded into water and carbon dioxide in the body, eliminating any toxicity problems. 
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Chitosan-DNA polyplexes possess mucoadhesive properties and, hence, are utilized in many 
nasal and oral gene therapy applications (Ramamoorth and Narvekar, 2015). Chitosan is 
soluble at pH <6 with the amine groups displaying a high density of positive charges, thereby 
increasing chitosan’s metal chelating properties (Narayanan et al., 2014) and stability. Hence, 
it has been used as a stabilizer contributing to steric hindrance and electrostatic repulsion in 
gold nanoparticles (AuNPs) (Mohd and  Johan, 2014). Chitosan functionalised AuNPs (CS-
AuNPs) will be discussed in section 2.3.3.  
The molecular weight of chitosan strongly influences its transfection efficiency, the higher 
the molecular weight the higher the transfection due to strong stabilization of chitosan-
nucleic acid complexes in vitro (Köping‐Höggård et al.,2003). However, high molecular 
weight chitosan has shown low solubility at neutral pH, large aggregated shapes, high 
viscosity and slow release of nucleic acids while low molecular weight chitosan has been 
associated with low complexation ability but better intracellular release of nucleic acids (Jin 
et al., 2014). Hence, the choice of chitosan of an optimal molecular weight is crucial for 
gene-delivery studies. The polycationic nature of chitosan results in strong electrostatic 
interactions with anionic nucleic acids, resulting in efficient complexation, condensation and 
protection of the nucleic acids from nuclease degradation. Chitosan also acts as a permeator, 
opening tight intercellular junctions in the cellular membrane and ensuring its delivery into 
the cell (Gascón et al., 2013). 
 
2.2.4 Poly-l-lysine  
Poly-l-lysine (PLL) is an extensively used cationic polymer and one of the first cationic 
polymers to be used in gene therapy (Jin et al., 2014) due to its ability to electrostatically 
interact with nucleic acids and cells.  PLL is derived from polymerisation of the N-carboxy-
anhydride component of lysine (Gascón et al., 2013). The different conformations of PLL’s 
secondary structure are influenced by temperature and pH. At 25°C, PLL exhibits a β-sheet 
conformation and at neutral pH forms an extended random coil due to the presence of 
repulsion forces as a result of protonation of the NH3
+ (Smirnovas et al., 2005). PLL has a 
large number of protonable amine groups and as the positive charge density of PLL increases 




In addition, the increase in the length of the polymer directly influences gene delivery 
efficiency and cytotoxicity (Segura and Shea, 2001). In normal cellular processes, PLL was 
found to stimulate immunoglobulin (interferon-β) production without hindering cellular 
proliferation (Stobiecka and Hepel, 2011). PLL has been shown to exhibit anti-tumour effects 
in L1210 lymphoid leukaemia, erythro-leukaemia, P388, Lewis lung, Ehrlich carcinoma and 
P38 macrophage derived tumour cell lines (Szende et al., 2002).  
Intravenous injection of PLL-DNA complexes conjugated to various targeting ligands of the 
asialoglycoprotein receptor and exhibited successful transient transgene expression in the 
liver of animal models (Wu et al., 2002). PLL functionalised AuNPs (PLL-AuNPs) will be 
discussed further in section 2.3.3. 
 
2.3 Inorganic Nanoparticles : Gold nanoparticles (AuNPs) 
 
Nanomedicine is the use of nanotechnology in medicine and is globally a fast-growing area 
for the treatment of various diseases, including cancer. It is a new and exciting branch of 
nanotechnology and utilizes nanosized particles or nanoparticles as carriers of genes or drugs. 
This application of nanoparticles, of which inorganic nanoparticles play a major role, is still 
under development and promises to revolutionize medicine. Over the years, an array of 
inorganic nanoparticles have emerged as potential genes and drug delivery systems having a 
dual function for imaging and therapeutics, giving rise to the intriguing area of theranostics. 
These inorganic nanoparticles that include carbon nanotubes, iron oxide, quantum dots and 
gold are being investigated in cancer therapy, bioengineering and gene therapy. Gold 
nanoparticles were used in this study and are hence discussed further in detail. 
 
Since the history of time, gold has captured the interest of scientists. Soluble gold was 
popular in Egypt and China in the 4th - 5th century B.C. with the first report of colloidal gold 
being the creation of ruby glass, ceramic and silk staining methods that are still in use today. 
In the middle ages, soluble gold was used for curative purposes to treat dysentery, heart 
disease, venereal problems, syphilis, epilepsy, ulcerative skin conditions and tumours 
(Pedrosa et al., 2015). It has been reported that reduction of aqueous chloroaurate using 
phosphorous in a two-phase system of CS2 produced a deep red AuNP solution which 
changed to blue-purple and to green upon drying (Faraday, 1857).  
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The first in vivo applications of AuNPs was in mice during the 1980’s and involved the use of 
27 nm PEGylated AuNPs functionalised with the recombinant human tumour necrosis factor 
alpha which displayed anti-tumour effects by apoptosis, cytolysis or cytostasis (Pedrosa et 
al., 2015). Subsequently, the first human clinical trials were conducted using these AuNPs 
(Libutti et al., 2010). During the 1990’s, various AuNPs formulations were shown as 
effective treatments for diseases such as rheumatism, tuberculosis and Lupus vulgaras (Does 
et al., 2003). The applications of AuNPs in nanomedicine have since expanded immensely.  
 
2.3.1 Properties of AuNPs 
One of the reasons that AuNPs have attracted favourable attention is due to their unique 
properties that include small size, different shapes, large surface-to-volume ratio, high 
stability, biocompatibility, oxidation resistance, intense surface plasmon resonance, high 
photothermal conversion rate and low toxicity (Deb et al., 2011). A distinctive physical 
property of AuNPs is their surface plasmon resonance (SPR) absorbance. The colour of a 
colloidal AuNP solution varies based on the size of AuNPs in solution with yellow to purple 
having a size range of 1-100 nm (Figure 2.3). The size of AuNPs influences their cellular 
uptake, release and clearance pathways, biodistribution and cytotoxicity. 
 
Figure 2.3: Various colours of colloidal AuNP solutions in relation to their size (Douma, 2008). The 




Generally, a size-relative absorption peak is observed in the 500-550 nm range, with an 
increase in size of the AuNPs causing an increase in the scattering, absorption wavelength 
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and total extinction, resulting in a change of colour of the solution (Jain et al., 2006). The 
SPR absorbance of colloidal AuNPs enhances their scattering and absorption optical 
properties (Long et al., 2009). Aggregation of AuNPs in solution due to a shift in the SPR 
absorbance of larger particles is indicated visually by a colour transition of the AuNP 
solution.  
AuNPs can be solids or a hollow shell and spherical, triangular, octahedral, sub-octahedral, 
tetrahedral, decahedral, multiple twined, icosahedral multiple twined, prisms, rods or 
hexagonal in shape (Figure 2.4). Each shape comes with its own set of properties and 
applications eg. gold nanorods are suitable for bio-sensing, photo thermal therapy and gene 
delivery while gold nanocages coated with temperature-sensitive polymers have been used as 

















Figure 2.4: Diagram depicting the various shapes of synthesized AuNPs (Khan et al., 2014).  
 
The surface of AuNPs consist of negative or positive charges, making them highly receptive 
to surface modifications by oppositely charged molecules via electrostatic interactions to 
either cations or anions (Pillay et al., 2010). The surface charge of AuNP-nucleic acid 
complexes influence their stability, intracellular uptake, cytotoxicity and release of the 
therapeutic cargo (Pedrosa et al., 2015). The stability of AuNPs is vital for their use as 
therapeutic agents as they are required to maintain their stability in the cellular environment 
and bloodstream. The chemical stabilization of AuNPs with sodium citrate and 
functionalisation with ligands imparts electrostatic and steric repulsion towards colloidal 
stability. Importantly, undesired interactions and the formation of protein coronas on the 
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surface of AuNPs may influence colloidal stability in biological systems. Colloidal stability 
of AuNPs can be manipulated by adjusting the pH of the solution, increasing electrolyte 
concentration, changing the stabilizing agent or medium and adding inorganic salts (Dukhin 
and Goetz, 2010).  
 
2.3.2 AuNP Synthesis  
Various methods for the synthesis of AuNPs have been employed and include physical, 
chemical and biological methods, producing AuNPs of desired size, shape and 
monodispersity. 
 
2.3.2.1 Chemical methods 
Chemical methods are most commonly utilized for the synthesis of AuNPs in liquid form. 
The basic principle of the chemical method is the conversion of Au3+ ions to Au0 (neutral) 
atoms by a reducing agent and, thereafter, a stabilizing agent is added to prevent aggregation 
of the resulting AuNPs. The most common reducing agents are sodium citrate and sodium 
borohydride. Stabilizing agents such as block co-polymers, peptide-biphenyl hybrids, 
polyvinyl pyrrolidine, bovine serum albumin, 1-octadecanethiol, 1, 5-pentanediol and 
cetyltrimethyl ammonium bromide (CTAB) are associated with the AuNP surface, providing 
charge, solubility and stability. 
The simplest and most popular method for colloidal AuNP synthesis is the Turkevich method 
(Turkevich et al., 1951) and adaptations, thereof, that produce 10-20 nm monodisperse 
colloidal AuNPs. This method utilizes hydrochloroauric acid (HAuCl4) reduced with sodium 
citrate which acts as an electrostatic stabilizing agent to prevent particle aggregation. This 
results in sub-nanometer particles in solution evidenced by a colour transition of the solution 
from yellow to wine-red (Figure 2.5). The size of the AuNPs are controlled by the reaction 
time and the amount of stabilizing agent used while its dispersion properties are controlled by 
the temperature of the reaction.  
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Figure 2.5: Reaction for the synthesis of AuNPs by sodium citrate reduction of HAuCl4 using the 
Turkevich method (Herizchi et al., 2016). 
 
The Brust-Schiffrin method produces thermal and air stable AuNPs of controlled size (5-6 
nm) and low dispersity in organic liquids such as toluene which are not miscible in water 
(Brust and Schiffrin, 1994). Reduction is achieved by sodium borohydride (NaBH4) which 
additionally acts as an anti-coagulant and initiates a colour transition of the organic phase 
from orange to deep brown. However, this method is laborious and requires several steps of 
purification.  
The seeding growth approach involves the reduction of previously synthesized AuNPs using 
the Turkevich method but reduced by hydroquinone producing AuNPs in the 30-300 nm 
range (Perrault and Chan, 2009). Modifications of this method have since been made, 
reducing the size distribution to 5-40 nm (Stanglmair et al., 2014). 
The ionic liquid synthesis method has more recently been introduced for the synthesis and 
stabilization of metal nanoparticles (Richter et al., 2013). These media, in addition to acting 
as reducing and stabilizing agents, have several advantages such as low melting points, non-
volatility, thermal stability and designable miscibility. A simple one-pot synthesis method of 
AuNPs utilizing N-(2-hydroxyethyl)-N-methylmorpholinium tetrafluoroborate has been 




2.3.2.2  Physico-Chemical methods  
These include photochemical, sonochemical and electrochemical methods. In photochemical 
synthesis, microwave irradiation using citric acid as a reducing agent, CTAB as a binding 
agent (Murawala et al., 2014) and  gamma irradiation using bovine serum albumin. The 
natural polysaccharide alginate as a stabilizing agent and have been used to synthesize 5-40 
nm AuNPs of controllable size and high purity (Rezende et al., 2010). Sonochemical 
synthesis using ultrasound produce AuNPs smaller than 10 nm in size (Baigent and Müller, 
1980). Adaptations on this method using reducing agents such as hydroxyl radicals and sugar 
pyrolysis radicals produced 30-50 nm nanoribbons which are extremely flexible and can bend 
at angles greater than 900. A disadvantage of this method is the production of AuNPs with a 
broad size distribution. The electrochemical production of nanoparticles producing size 
selective nanoscale transition metal particles, stabilized by tetra alkyl ammonium salts, have 
been reported (Reetz and Helbig, 1994).  
 
This method has advantages such as low cost, modest equipment, high quality, lower 
temperatures and ease of controlling the yield of the product (Herizchi et al., 2016).  
 
2.3.2.3. Biological methods   
Recently, biological synthesis termed the ‘green synthesis’ of nanoparticles was developed as 
an alternative eco-friendly method using non-toxic regents, cost-effective and renewable 
materials. This method is not energy consuming and does not require the need for the 
disposal of hazardous chemicals. Biological methods entail the use of microorganisms, 
enzymes, plants and plant extracts (Mohanpuria et al., 2008). Natural biomaterials such as 
egg-shell membranes, chitosan and edible mushrooms have been used to synthesize AuNPs. 
Sun light irradiation has additionally been used as a reducing agent with the aid of 6-
mercaptourine and folic acid as stabilizing agents (Lan et al., 2013). Although these 
biological methods are environmentally friendly, they are associated with many 
disadvantages such as  non-uniform shapes, poor mono-dispersity, random aggregation and 
low scale-up, rendering them  unappealing for use in comparison to the chemical methods 





2.3.3 Functionalisation of AuNPs with Cationic Polymers (CPs) 
The purpose of nanoparticle surface functionalization is to modulate the reactivity, toxicity, 
stability, shape and size to enhance the rate of uptake and tissue biocompatibility in a 
biological environment (Sivaramakrishnan et al., 2014). For in vivo applications, surface 
modification regulates the circulation half-time and systemic clearance of these nanoparticles 
with enhanced bioavailability, low immunogenicity and target specific accumulation 
(Baptista et al., 2015). AuNPs allow for easy functionalization and binding with targeting 
agents and drugs in therapeutic applications due to their high surface-to-volume ratio (Yeh et 
al., 2012). The strong binding efficiency of AuNPs to ligands such as thiols, disulphides and 
amines also facilitate their conjugation with biomolecules such as DNA, RNA and antibodies 
(Balasubramanian et al., 2010).  
AuNP nanocarriers allow for the protection of their therapeutic cargo by the prevention of 
degradation before the biological target is reached (Pedrosa et al., 2015). The interactions 
involved during functionalisation include covalent and non-covalent conjugation to AuNPs. 
The loading efficiency is dependent on the quantity of functional ligands and the reaction 
time. Non-covalent conjugation involves different interactions such as electrostatic 
interactions, specific binding affinity and hydrophobic interaction. It is the simplest way of 
conjugation. Although, covalent conjugation is known to produce stable constructs (Yeh et 
al., 2012), non-covalent conjugation reduces the risk of altering the structure and function of 
the AuNPs or the therapeutic cargo (De Long et al., 2010). 
For the transport of nucleic acids such as mRNA which is negatively charged there is a 
requirement for the electrostatic complexation of the nucleic acid with a positively charged 
agent for cellular internalization. Cationic polymers (CPs) are considered most suitable for 
the functionalization of the neutral AuNPs due to their abundance of positively charged 
groups in their structure. Polymers are used to functionalise AuNPs interact and overlap each 
other in solution giving rise to repulsive osmotic forces by the compressed polymer segments 
associated with unfavourable entropy (Cosgrove, 2005). This type of force is also referred to 
as steric repulsion and prevents the AuNPs from aggregating. Chitosan (CS) and poly-l-lysine 
(PLL) functionalization of AuNPs are employed in this study and will be briefly discussed. 
As a metal chelator, chitosan can reduce gold precursors and stabilize the resulting AuNPs. 
CS-AuNPs offer a platform for cross-linking due to chitosans’ cationic properties and amino 
groups and can be functionalised further with various biomolecules for gene delivery. CS-
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AuNP conjugates have been developed into useful tools as antibacterial and antifungal 
agents, for gene and drug delivery, bio-sensing and tumour targeting and have been 
recommended for insulin delivery by oral and nasal administration (Boyles et al., 2015). It 
has been reported that CS-AuNPs maintain and enhance treatment efficacy, extends systemic 
circulation time, enhances cellular uptake efficiency, widens intracellular distribution and 
prevents undesired degradation of the therapeutic gene through various uptake mechanisms 
such as micropinocytosis (Nam et al., 2009). These properties bode well for use of CS-
AuNPs in cancer gene therapy applications. 
The gene delivery efficiency of PLL by itself is relatively low but conjugation with other 
vectors such as AuNPs facilitate better cellular uptake and gene expression. The direct 
interaction of AuNP and PLL  surface stabilizes the AuNPs in solution (Joshi et al., 2004). 
PLL-AuNPs have exhibited efficient electrostatic binding of nucleic acids and penetration of 
eukaryotic membranes with low cytotoxicity (Stobiecka and Hepel, 2011). PLL may be 
adsorbed electrostatically onto the surface of AuNPs, depending on the overall charge of the 
AuNPs (Figure 2.6).  
Citrate stabilization confers a negative charge on the AuNP surface which enhances the 
electrostatic binding of AuNP to PLL. Apart from electrostatic interactions, hydrogen 
bonding occurs between the PLL chains and citrate molecules on the surface of citrate-
capped AuNPs (Figure 2.7). All these interactions result in the formation of a condensed 
structure which is efficient for binding and protecting nucleic acids in gene delivery 
applications. PLL-AuNPs have also been used to develop bactericidal and viricidal vaccines 
as scaffolds in tissue repair and as stem cell carriers (Ghosh et al., 2008).  
 





Figure 2.7: Hydrogen bonding between PLL and citrate capped AuNPs (Stobiecka and Hepel, 2011). 
 
 
2.3.4 Gene delivery and Gold Nanoparticles 
Plasmid DNA (pDNA), anti-sense oligonucleotides, small-interfering RNA (siRNA) and 
micro RNA (miRNA) are most commonly used in gene therapy applications. In the case of 
pDNA, it is transcribed into messenger RNA (mRNA) and translated into the desired protein 
as a replacement for or to supplement a faulty gene-encoded protein. Anti-sense 
oligonucleotides are short, single stranded nucleotide sequences (25 bases or less) that have 
shown potential in gene therapy applications. These oligonucleotides are designed to be 
complementary to a specific sequence of mRNA, bringing about inhibition. However, they 
have a short half-life and are rapidly degraded by nucleases. For gene silencing in gene 
therapy, both siRNA and miRNA can be employed. The use of these strategies are associated 
with high targeting specificity, coupled with a high and prolonged effect on gene silencing 
(Gardlík et al., 2005). 
To date, there has been limited success in gene expression studies using the above nucleic 
acids, leading to the investigation of other nucleic acids such as mRNA as an alternative to 
pDNA. This thesis is based on the AuNP delivery of mRNA which will be elaborated upon. 
The use of mRNA holds promise for efficient gene expression and overcoming the cellular 
barriers limiting the use of pDNA and is therefore investigated in this study. mRNA are short 
10 kb sequences of ssRNA consisting of five components: the 5’ cap, 5’ untranslated region, 







The non-coding 5’ untranslated region which has a high G-C content plays a role in the post-
transcriptional regulation of gene expression and allows for excellent control over the protein 
product by modulating stability, transport, sub-cellular localization and translation efficiency 
of the mRNA (Tavernier et al., 2011). The 3’ untranslated region is A-U rich and functions in 
a similar manner. The poly (A) tail ( 200 A residues) and 5’ cap determine the efficiency of 
translation and stability of the mRNA (Yamamoto et al., 2009). In this study, a reporter 
mRNA (Fluc-mRNA), incorporating the firefly luciferase gene in the open reading frame, is 
used to evaluate gene expression.  
 
 
Figure 2.8: mRNA structure and components (Youn and Chung, 2015). 
 
2.3.4.1 Intracellular Trafficking 
Effective gene delivery is dependent on the type of the carrier, its interaction with serum, 
circulation time, bio-distribution, evasion of immune cells and macrophages, cell surface 
interaction and penetration, endosomal escape, protection from degradative nucleases, 
transport to the nucleus, persistence as an extrachromosomal element or integration into the 
genome and sustained gene expression (Lundstrom and Boulikas, 2003).  
CPs and polymeric nanoparticles associate with the cellular membrane via electrostatic 
interactions, resulting in internalization by receptor-mediated endocytosis, adsorptive 
endocytosis, clathrin-coated pits, phagocytosis or caveolae (Wiethoff and Middaugh, 2003). 
Once in the cells, cationic polymeric nanoparticles with  protonated amine groups at a pKa 
close to the endosomal or lysosomal pH, utilize the proton sponge effect with an influx of H+, 
Cl- and water causing the endosome to swell and rupture releasing its contents (Elsabahy et 
al., 2011). In addition, they electrostatically interact with the anionic structures of the 
endosome in the flip-flop mechanism, resulting in a lateral diffusion of CPs and the release of 




Figure 2.9: Mechanism of cationic polymer-based nanoparticle gene delivery and expression (Jin et 
al., 2014). 
 
In an in vivo system, naked nucleic acids encounter extracellular and intracellular enzymes 
which rapidly degrade the nucleic acids (Yellepeddi, 2015). Polymeric nanoparticles are 
efficient at condensing and protecting nucleic acids, exhibiting excellent colloidal stability 
and shielding the therapeutic cargo from the harsh effects of biological and cellular 
environments. Foreign nucleic acids are known to activate immune responses, resulting in the 
production of inflammatory cytokines (Kreiter et al., 2011) which can be avoided by 
complexation with CPs that are biocompatible and mask the foreign characteristics of the 
therapeutic nucleic acids. Compared to pDNA, mRNA is devoid of immunogenic CpG motif 
sequences and  is less toxic as it contains no viral promoters or bacterial sequences in its’ 
structure (Tavernier et al., 2011). 
pDNA must be first translocated from the cytoplasm to the nucleus for transcription before 
translation and gene expression. In contrast, mRNA molecules do not need nuclear entry for 
gene expression as mRNA is already in transcript form and the translation of mRNA to 
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protein occurs in the cytoplasm. Hence, it evades the nuclear barrier and expresses the 
therapeutic gene quicker than pDNA (Figure 2.10).   
 
Figure 2.10: DNA and mRNA gene expression pathways (Thermo Fisher Scientific, 2016). 
 
mRNA transfection is independent of the cell-cycle and can be used to transfect non-dividing 
and dividing cells since mRNA does not require nuclear membrane degradation during the 
replication cycle for translation. Hence, mRNA  can be used for hard-to-transfect cells such 
as endothelial and dendritic cells (Yamamoto et al., 2009).  With mRNA transfection there is 
no risk of insertional mutagenesis as protein translation from mRNA occurs independently 
without integration into the cellular genome, resulting in transient expression of the 
therapeutic protein.  The use of mRNA-based gene transfer in combination with CP 






2.3.4.2 Cellular uptake 
Cellular uptake of AuNPs depends on their physiochemical characteristics such as shape and 
size which ensure that absorption, penetration, circulation and distribution of AuNPs are 
easily achieved in bio-systems (De Jong et al., 2008). Passive or active targeting mechanisms 
can be used for the delivery of AuNP therapeutics into cells (Figure 2.11). The enhanced 
permeability retention factor effect (EPR) is associated with passive targeting wherein 
AuNPs accumulate in the tumour due to increased vasculature, allowing passage through the 
endothelium for delivery at the tumour site with reduced systemic toxicity (Kennedy et al., 
2011).  
Passive cellular uptake of AuNPs involves mechanisms such as endocytosis, pinocytosis, 
clathrin-coated pits, phagocytosis or caveolae with  pinocytosis being the most dominant 
internalisation pathway for AuNPs in several cell lines (Huefner et al., 2014). These 
pathways follow a general process of cell membrane receptor recognition, engulfment into 
vesicles, penetration into cells, signal pathway activation, trafficking and storage or 
elimination of the AuNPs.  
Active targeting is dependent on a functional surface ligand for targeting, selectivity and 
specificity using receptor-mediated endocytosis and cargo release inside the cell (Matsui et 
al., 2015). AuNPs functionalised with bombesin peptide was successfully used to target the 
gastrin-releasing peptide receptor overexpressed in the breast, prostate and small-lung 
carcinomas (Manjila et al., 2013). Other overexpressed receptors (such as the epidermal 
growth factor and folate receptors) on cancer cells have successfully been targeted using their 




Figure 2.11: Representation of passive and active cellular uptake of AuNPs (Ghosh et al., 2008). 
 
The prevention of aggregation of AuNPs is crucial as this increases their size, restricting easy 
translocation across membranes (Gosens et al., 2010). Furthermore, plasma proteins may 
adsorb onto the surface of the AuNPs, altering these properties (Vijayakumar and Ganesan, 
2012). The formation of a protein corona on the AuNP surface increases their stability and 
may be a possible mechanism for the recognition and internalisation of AuNPs into the cells 
(Giljohann et al., 2007). The absorption of proteins may cause aggregation and opsonisation 
of the nanoparticles in vivo, shortening systemic circulation and reducing the enhanced 
permeation and retention effect (Kim et al., 2015).  
The size of AuNPs influences many factors such as cellular adhesion and interaction, 
deposition, translocation, biodistribution, circulation time and fate, both in vitro and in vivo. 
AuNPs from 1-18 nm in size have been reported to easily cross the cell membrane and enter 
the nucleus to interact with the DNA (Gao et al., 2011). The cellular uptake efficiency of 20 
nm polystyrene coated AuNPs in the human hepatocyte cell line (HepG2) and the primary rat 




AuNPs are also capable of crossing the blood-brain and placental barriers, thereby 
accumulating within neural tissue, placenta and foetus. Several studies have reported these 
observations using maternal rat models and intravenous injections of various sizes of AuNPs 
(Myllynen et al., 2008; Takahashi and Matsuoka, 1981). There are two possible mechanisms 
of AuNP biodistribution in vivo, namely transport by endocytotic-exocytotic and paracellular 
transport mechanisms which include the transport of molecules around cells and via tight 
junctions of epithelial cells (Mühlfeld et al., 2008). These mechanisms are not only 
influenced by the size of AuNPs but also their surface properties, type of animal models and 
the exposure route. 
Functionalisation with ligands and various biochemical molecules influences the 
bodistribution of AuNPs within in vivo applications (Niidome et al., 2006). PEG is an anti-
fouling polymer which prevents opsonisation by creating stealth AuNPs and extending their 
circulation period CS-AuNPs were found to transverse the cell membranes of Chinese 
hamster ovary cells by endocytosis (Boca et al., 2011) and the outer cell membrane of THP-1 
monocytic cells and the plasma membrane of lysosomes by exocytosis (Boyles et al., 2015).  
The surface charges present on AuNP surfaces have shown to enhance their uptake into cells. 
For positively charged amine functionalised AuNPs, the mechanism of internalization 
involves their interaction with the negatively charged cell membrane (Sandhu et al., 2002). 
Several reports have proven the superiority of positively-charged AuNP cellular uptake in 
comparison to negatively-charged AuNPs (Bartneck et al., 2012). Cationic AuNPs were seen 
to be internalised by THP-1 monocytic cells within 30 min whereas anionic AuNPs 
internalisation occurred only after 6 hours (Boyles et al., 2015). These findings can be 
attributed to the repulsive forces between negatively-charged AuNPs and the negatively-
charged cell membrane. In terms of intracellular trafficking, cationic AuNPs have exhibited 
perinuclear arrangement whereas anionic AuNPs remain in endocytic vesicles (Shukla et al., 
2005).  
Cellular internalization of AuNPs has shown to be dependent on cell type, concentration and 
incubation time. Internalization is also likely to differ for different preparations of AuNPs due 
to their variations in size, charge and surface chemistry (Choi et al., 2013).  It has been 
reported that cationic AuNPs depend on endocytosis for cellular transport and uptake (Lin et 
al., 2013). After endocytosis, the endo-lysosomal compartment facilitates the degradation of 
biodegradable AuNPs. Those that are non-degradable are excreted along with phagocytosing 
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cells (Pan et al., 2007). In vivo, this occurs by excretion in faeces or expectoration by the 
lung.  
 
2.3.4.3 Transfection Efficiency 
Transfection efficiency and release of the therapeutic payload are improved by the   
hydrophobicity of the AuNPs that have been functionalised with CPs or other positively-
charged biomolecules (Rana et al., 2012). Positively charged AuNPs have shown an overall 
trend of efficient nucleic acid condensation, protection, delivery and expression. Cationic 
AuNPs with amino-based side chains are more efficient for DNA transfection (Kim et al., 
2006) compared to neutral and anionic AuNPs. Due to the positive charges of surface-
functionalised AuNPs at physiological pH, the nanoconjugates interact strongly with 
negatively charged nucleic acids. The ratio of positive charges present on the amines to the 
negative charges present on the selected nucleic acid and the concentration and length of the 
amine chains are factors which have been shown to influence the efficiency of nanoparticle 
mediated gene delivery.  
Simple cationic primary amine groups used to functionalise AuNPs can increase gene 
delivery and transfection efficiency (Noh et al., 2007) . PLL-AuNPs have been shown to be 
highly efficacious for the delivery of plasmid DNA and surpasses most commercial vectors 
(Ghosh et al., 2008). CS-AuNP/DNA complexes have shown enhanced transfection 
efficiency in murine monocyte-macrophage cells (RAW264.7 cells) which was attributed to 
the stability of the CS-AuNPs in serum (Zhou et al., 2008).  To date, most investigations have 
covered AuNPs for pDNA, siRNA and miRNA delivery with limited reports on the use of 
AuNPs or CP-AuNPs for the delivery of mRNA which theoretically is a far superior nucleic 
acid in terms of achieving the goal of gene therapy as explained earlier.  
In this study, we have evaluated the transfection efficiency and transgene expression in 
normal and cancer cell lines as a means to assess the potential of CP-AuNPs as vectors for 
the delivery of mRNA with the aim of the formulation of vaccines for the immunotherapy of 
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Gold nanoparticles (AuNPs) have recently shown immense potential in clinical medicine and 
therapeutic delivery applications due to their many desirable properties that include stability, 
high dispersity, small size, surface plasmon resonance (SPR), low cytotoxicity and 
biocompatibility. Advances in clinical medicine have highlighted gene therapy as a promising 
technique for the treatment of numerous life threatening diseases such as cancer. In recent 
studies, plasmid DNA has been routinely utilized for gene therapy. However, its use has 
crucial limitations such as the requirement of intracellular trafficking and nuclear entry for 
efficacious gene delivery. In comparison, mRNA molecules possess the ability to overcome 
these barriers. In this study, we exploit the above mentioned desirable properties using 
chitosan functionalised AuNPs as vehicles for mRNA delivery and assess the degree of 
transgene expression in three human cell lines: embryonic kiney (HEK293), colorectal 
adenocarcinoma (Caco-2), and breast adenocarcinoma (MCF-7). AuNPs were synthesized 
and successfully functionalised with chitosan (CS). All nanoparticles (AuNPs and CS-
AuNPs) and the nanocomplexes (CS-AuNP:Fluc-mRNA) were characterized using UV-Vis 
spectrophotometry, Transmission Electron Microscopy (TEM) and Nanoparticle Tracking 
Analysis (NTA). CS-AuNP:Fluc-mRNA binding, compaction and nuclease protection were 
evaluated using the band shift, dye displacement and nuclease protection assays, respectively. 
The degree of cytotoxicity of the complexes to the mammalian cells was evaluated using the 
MTT reduction assay and gene expression experiments were conducted using the luciferase 
reporter gene assay. In addition, these assays were also conducted on pure CS:Fluc-mRNA 
complexes for a comparative analysis against the AuNP nanocomplexes. Results indicate that 
CS-AuNPs and their nanocomplexes exhibit suitable and favourable properties such as small 
size (CS-AuNP: 69 ± 15.2 nm, nanocomplexes: 95 ±9.9 nm), stability (zeta potential: CS-
AuNP: 55.5 ±1.2 mV, nanocomplexes: 25.9 ±0.5 mV), excellent binding, low cytotoxicity, 
and effective transgene expression. In addition, CS-AuNPs proved to be more efficient than 
the CS polymer itself, indicating that AuNPs greatly improve the biological properties and 
functions of chitosan. Overall, these results bode well for the use of CS-AuNPs as potential 
vehicles for the delivery of mRNA in biomedical applications, especially in cancer treatment 
and immunotherapy. 




3.1  Introduction 
Cancer is a scientific term used for the complex collection of diseases which entail a 
sequence of molecular events that primarily alter the normal properties of cells (Does et al., 
2003). As a result, these altered cells divide uncontrollably and invade surrounding tissues, 
overcoming the normal control systems. The development of cancer may be caused by a 
variety of factors such as improper diet and exercise, exposure to certain physical and 
chemical agents, infection, radiation, inadequate hormone levels and inherited genetic defects 
(Cancer Association of South Africa, 2016). Progress in the study of treatments has increased 
immensely over the years, providing us with methods such as surgery, cryosurgery, 
chemotherapy, radiation, laser, hyperthermia, photodynamic, hormone, transplant, biological 
and targeted therapy (American Cancer Society, 2014). Despite this progress, cancer remains 
one of the leading causes of death worldwide with 8.2 million deaths reported in the year 
2012 (International Agency for Research on Cancer and World Health Organization, 2014). 
As a major health concern for Africa, 715 000 new cancer cases and 54 000 cancer deaths 
occurred in 2008, with projections for the year 2030 predicting that these figures will in fact 
double (International Agency for Research on Cancer and Cancer Research UK, 2014). Due 
to the high mortality rate and the lack of fully operational treatments, it is imperative to study 
and develop novel treatment strategies with the purpose of alleviating the burden caused by 
cancer. 
In this regard, it has been reported that gene therapy is a promising novel technique for the 
treatment of numerous incurable diseases such as cancer (Ibraheem et al., 2013). Gene 
therapy is defined as a method for the introduction of a functioning gene into cells to correct 
a cellular dysfunction or to offer a different cellular function in order to provide therapeutic 
benefit (Cotrim and Baum, 2016). There are several approaches to elicit the correction of a 
cellular dysfunction such as replacing the abnormal gene with a normal gene through the 
process of homologous recombination or returning the gene to its normal function by 
repairing the abnormal gene through selective reverse mutation and altering the regulation of 
a disease specific gene (Patil et al., 2012). Since the revolutionary experimentation by 
Malone et al. in 1989 involving the successful delivery of mRNA using cationic lipids, very 
few studies using mRNA have been reported (Bettinger et al., 2001) with plasmid DNA 




In comparison, mRNA based transfection provides many advantages over pDNA, for 
example there is no requirement for nuclear entry and the protein is expressed directly in 
cytoplasm, hence faster gene expression. Furthermore, there is no genomic integration. 
Protein expression is promoter-independent and it is suitable for hard-to-transfect cells 
(Matsui et al., 2015). To date, gene therapy has utilized two main vector systems viz., viral 
and non-viral as carriers for these therapeutic genes. However, the better choice of study 
points at non-viral vectors due to the fact that viral vectors are known to elicit immune 
responses. The size of genetic material that can be inserted is limited and they are difficult to 
prepare in large quantities and are highly expensive (Ibraheem et al., 2013). The challenge of 
gene therapy, currently, is in the development of safe and suitable carriers for efficient gene 
transfer. The carrier should meet the following criteria: protection of the gene from nucleases 
present in the cells, low or no cytotoxicity and effective transfer of the gene to the nucleus 
(Manjila et al., 2013).  
Gold nanoparticles (AuNPs), in particular serve as excellent candidates for nucleic acid 
delivery applications (Ding et al., 2014). This is due to their many desirable properties such 
as its biocompatibility, safety and relatively inert core (Rana et al., 2011). Additionally, their 
relative ease of synthesis producing various shapes and sizes while controlling dispersity, 
high chemical stability, powerful surface plasmon resonance (SPR) and photothermal 
conversion rate have made AuNPs to be potentially good theranostic tools (Pedrosa et al., 
2015). Above all, their high surface-to-volume ratio allows AuNPs to have a dense loading 
capacity in which they can be functionalised with many biological ligands and therapeutic 
molecules (Rana et al., 2011). It has been reported that more than 100 ligands can be 
conjugated to a 2 nm AuNP core (Hostetler et al., 1998). Carriers which incorporate cationic 
polymers are attractive due to their ease of synthesis and ability to integrate several functional 
groups within the same molecule without compromising nucleic acid binding ability (Zhou et 
al., 2008). Among these cationic polymers, chitosan has been chosen as an ideal candidate for 
functionalisation as it is non-toxic, biodegradable, biocompatible, able to interact and 
permeate the cell membrane making it an effective adjuvant (Boyles et al., 2015). 
Functionalisation with chitosan reduces AuNP precursors due to the polyelectrolyte 
behaviour provided by its protonated amine groups resulting in the stabilization of the AuNPs 
(Narayanan and Sivakumar, 2014).  
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In this study, we synthesized and characterized chitosan functionalised AuNPs using various 
chemical and physical techniques, assessed their ability to bind and protect luciferase-
encoded mRNA (Fluc-mRNA) and finally evaluated their cytotoxicity, transfection efficiency 
and apoptosis induction in three mammalian cell lines (HEK293, Caco-2 and MCF-7) with 
the aim of determining their effectiveness as gene therapy vectors for cancer treatment. 
 
3.2  Materials and methods 
For the preparation of all reagents and solutions, Ultrapure (18 M ohm) deionized water 
(Milli-Q Academic, Millipore, France) was utilized. All reagents and chemicals were 
commercially purchased and of analytical grade.  
3.2.1 General materials and reagents 
Gold (III) chloride trihydrate (Mw: 393.83 g/mol, HAuCl4.3H2O), chitosan ≥ 75% 
deacetylated, saccharose (Sucrose, Mw: 342.30 g/mol, C12H22O11), 2, 2-dihydroxyindane-1, 3-
dione (Ninhydrin, Mw: 178.14 g/mol, C9H6O4) were supplied by Sigma-Aldrich Chemical 
Co., (St. Louis, USA). Sodium citrate tribasic dehydrate (Mw: 294.20 g/mol, 
Na3C6H5O7.2H2O), 2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulphonic acid (HEPES, 
C8H18N2O4S), tris (hydroxymethyl) aminomethane [Tris base, Mw: 121.14 g/mol, 
H2NC(CH2OH)3], sodium dihydrogen orthophosphate dehydrate (Mw: 156.01 g/mol, 
NaH2PO4.2H2O), ethylene diamine tetra acetic acid disodium salt (Mw: 372.24 g/mol, EDTA, 
C10H14N2Na2O8.2H2O), dodecyl sulphate sodium salt (SDS, Mw: 288.37 g/mol, 
C12H2OSO2Na ), bromophenol blue (Mw: 669.96 g/mol, C19H10Br4O5S) were supplied by 
Merck (Darmstadt, Germany). Glacial acetic acid (Mw: 60.05 g/mol, CH3COOH) was 
supplied by BDH Chemicals Ltd. (Poole, England). UltraPure
TM agarose, RNase free water (1 
U/µl, supplied with MnCl2) and UltraPure
TM DEPC-treated water were supplied by Thermo 
Fischer Scientific Inc., (Waltham, Massachusetts, USA).  Molecular grade ethidium bromide 
solution (10 mg/ml) [3, 8-Diamino-5-ethyl-6-phenylphenanthrinidium bromide, Homidium 
bromide, EtBr, (Mw: 394.31 g/mol, C21H20BrN3) was supplied by Promega (Madison, 
Wisconsin, USA).  Fetal Bovine Serum (FBS) was supplied by Hyclone
 GE Healthcare (Utah, 
USA). SYBR Green II RNA gel stain (10 000× concentrate in DMSO) was supplied by 
Cambrex Bio Science Rockland Inc., (Rockland, ME). The Fluc-mRNA was provided by the 
43 
 
Laboratory of Molecular and Cellular Therapy, Department of Immunology-Physiology, 
Vrije University, Brussels, Belgium.  
 
3.2.2 Experimental methods 
 
3.2.2.1 Colloidal AuNP synthesis by citrate reduction 
An aqueous colloidal AuNP solution with a concentration of 0.45 x 10-3 M   was prepared by 
the HAuCl4 reduction method adapted from Turkevich et al., 1951 (Figure 3.1). 
Approximately 25 ml of 18 M ohm water was heated to 90ºC and maintained at this 
temperature with constant mixing at a medium speed for the remaining steps using a MH-4 
Analog heating magnetic stirrer (Fried Electric, Israel).  Thereafter, 375 µl of a 3 x 10-2 M 
Gold (III) chloride trihydrate solution was added to the water, followed by the addition of 1 
ml of a 1% (w/v) sodium citrate solution. The solution was then boiled for a further 15 
minutes, taking note of the colour transitions during the boiling period as outlined in Figure 
3.2. The colour changed within 2-3 minutes from pale yellow to dark blue, to black and after 
10 minutes to ruby red, denoting the formation of the desired AuNPs. This solution was then 
boiled for a further 5 minutes and thereafter allowed to cool and stored at room temperature.  
 
 
Figure 3.1: Diagram depicting the formation of a citrate reduced AuNP core resulting from the 
Turkevich method (Bahadur et al., 2013). 
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Figure 3.2: Schematic representation of the colour transitions observed during the synthesis of 
AuNPs. 
 
3.2.2.2 Functionalisation of AuNPs with chitosan 
A primary chitosan stock solution (1 mg/ml) was prepared by dissolving 50 mg of chitosan 
(CS) in 50 ml of 1% glacial acetic acid. For experimental use, a 0.025 µg/µl CS solution was 
prepared from the primary stock solution (1 mg/ml). 
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Functionalisation was carried out by the drop-wise addition of 1 ml of the AuNP solution to 1 
ml of the CS primary stock solution (1 µg/µl) under constant moderate vortexing using a 
Genie 2 vortex (Scientific Industries, USA) producing CS functionalized gold nanoparticles 
(CS-AuNPs) with a AuNP:CS ratio of 1:1, (Figure 3.3). The final concentration of CS in 
solution was calculated to be 0.5 µg/µl as a result of dilution and was used in calculations for 
the subsequent protocols. A 0.025 µg/µl of CS-AuNP solution was prepared by dilution and 
all solutions then stored at room temperature.  
 
Figure 3.3: Image of CS functionalised AuNP (CS-AuNP) solution. 
Dialysis of the CS-AuNP solution was conducted to remove any unbound polymer from the 
solution and to determine the binding efficiency of the AuNPs to CS. The CS-AuNP solution 
was dialysed against 400 ml of 18 M Ohm water at room temperature for 2 hours using a 
cellulose dialysis membrane [(MWCO: 12-14000 Daltons, Sigma-Aldrich, USA]. 
 
3.2.2.3 Elemental verification of synthesized nanoparticle solutions 
Prior to conducting any experimental analysis on the synthesized AuNP and CS-AuNP 
formulations, Inductively Coupled Plasma (ICP), Fourier Transformed Infrared Spectroscopy 
(FTIR) and the qualitative ninhydrin test were performed in order to verify the successful 
synthesis of these nanoparticle solutions based on their composition. 
 
3.2.2.3.1 Inductively Coupled Plasma (ICP) analysis 
Elemental detection and quantification of the Au concentration in the AuNP solution was 
examined by inductively coupled plasma-optical emission spectroscopy (ICP-OES), 
performed on a Perkin Elmer Optima 5300 DV Optical Emission Spectrometer. A standard 
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calibration curve was set up between 1 and 20 ppm using a 100 ppm Au standard stock 
solution purchased from Fluka for the analysis. 
 
3.2.2.3.2 Fourier Transformed Infrared Spectroscopy (FTIR) analysis 
FTIR analysis of the AuNPs was conducted in a Spectrum Perkin Elmer spectrophotometer, 
precisely equipped with a Universal ATR sampling accessory using a diamond crystal. 
Spectrum Analysis Software was used to obtain the respective IR spectra. 
 
3.2.2.3.3 Qualitative ninhydrin test for amino acids  
A simple test to validate the successful functionalisation and verification of the presence of 
CS via its amine groups in the CS-AuNP solution was carried out using the qualitative 
ninhydrin reaction. Briefly, to 1 ml of the CS-AuNP solution was added 1 ml of a 0.1% 
ninhydrin solution and the mixture boiled for 3-5 minutes in a boiling water bath. Thereafter, 
the mixture was cooled and the presence or absence of a clear to blue/purple colour transition 
recorded was indicative of the presence of the amine functionality and hence successful 
functionalisation. 
 
3.2.2.4 Formation of mRNA:NP complexes  
Lyophilised Fluc-mRNA (50 µg) was dissolved in 200 µl of RNase-free water and the stock 
solution stored at 40C. The purity and concentration of the stock solution was verified and 
confirmed to be 0.25 µg/µl using a Nanospec 2000C spectrophotometer. The CS-AuNP 
solution (0.025 µg/µl) was sonicated for 1 minute in a Transsonic 460/H sonicator (Elma 
Schmidbauer GmbH, Germany) to evenly disperse the AuNPs in solution. The complexes 
were prepared by adding Fluc-mRNA (0.25 µg/µl) to increasing amounts of the CS-AuNPs 
and CS, respectively, to create various CS-AuNP/CS:Fluc-mRNA (w/w) mass ratios. CS on 
its own was included for comparison with CS-AuNP to verify if there are any enhanced 
properties due to functionalisation with AuNPs, over CS by itself.  Thereafter, the complexes 
were made up to a final volume of 10 µl with HEPES buffered saline [HBS, (20 mM HEPES; 
150 mM NaCl), pH 7.4]. The mixtures were then incubated at room temperature for 30 
minutes to allow for the formation of CS-AuNP/CS:Fluc-mRNA complexes. 
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3.2.2.5 Characterization of nanoparticle and nanocomplexes  
 
3.2.2.5.1 UV-Vis optical spectrophotometry analysis  
The formation of nanoparticle solutions were monitored using UV spectrophotometry. The 
absorbance (Abs) readings of the AuNPs, CS-AuNPs and CS-AuNP:Fluc-mRNA [Ratio 
0.4:1 as prepared (3.2.2.4) and outlined in Table 3.1] solutions were measured over a 
wavelength range of 200 nm - 800 nm using a Biomate 3 spectrophotometer (Thermo Fischer 
Scientific Inc., Waltham, Massachusetts, USA) with 18 M ohm water as a blank. A UV 
spectrum was acquired and recorded as a plot of absorbance versus wavelength (nm) for each 
solution and compared to previous literature to confirm the expected SPR absorption of 
AuNPs in the range of 510 nm - 550 nm (Verma et al., 2014). UV spectrophotometry was 
also conducted on the dialysed CS-AuNP solution which provided an indication of the 
binding efficiency, using the formula: Unbound CS (%) = (Abs before dialysis – Abs after 
dialysis/Abs before dialysis) x 100% and thus bound CS (%) = 100% - unbound CS %. 
 
3.2.2.5.2 Transmission Electron Microscopy (TEM) 
The shape, morphology, uniformity and distribution of all nanoparticle and nanocomplexes 
were evaluated using transmission electron microscopy. Approximately 1 µl of AuNP, CS-
AuNP and CS-AuNP:Fluc-mRNA (0.4:1 w/w) solutions were added to separate carbon 
coated Formvar grids and air-dried before viewing. Samples were viewed using a JEOL-JEM 
TEM1010 (Jeol, Tokyo, Japan) without warming above -150ºC at an acceleration voltage of 
100 kV. Images were captured using the iTEM Soft Imaging Systems (SIS) Megaview III 
fitted with a side-mounted 3-megapixel digital camera. 
 
3.2.2.5.3 Nanoparticle Tracking Analysis (NTA) 
The average size and concentration of nanoparticles in solution based on particle-particle 
analysis was determined using Nanoparticle Tracking Analysis (NTA) which also determines 




The Nanosight NS500 Nanoparticle characterization system and NTA version 3.2 Software 
(Malvern Instruments Ltd., Worcestershire, UK) were used. The system was first primed and 
flushed with 18 M Ohm water, removing any trapped air bubbles and any residual mobile 
matter off the stage to ensure accurate readings.  For this analysis, AuNP, CS-AuNP (1/500 
dilution) and CS-AuNP:Fluc-mRNA (1/100 dilution) solutions were examined.  
 
3.2.2.6 Assessment of CS and CS-AuNP binding to Fluc-mRNA 
 
3.2.2.6.1 Gel retardation assay 
The minimum concentration of CS-AuNP and CS required to fully bind 0.25 µg/µl of Fluc-
mRNA and the optimal ratio for complex formation was determined using the band shift or 
gel retardation assay.  
A 2% (w/v) agarose gel containing 3 µl of ethidium bromide (10 mg/ml), 2 ml of 10 x Tris-
phosphate-ethylenediamine tetra acetic acid (EDTA) [TPE] electrophoresis buffer fitted with 
an 8 well comb was prepared. The agarose gel was allowed to polymerise for approximately 
1 hour on a flat surface, after which the comb was carefully removed and the casting tray 
placed into a Mini-Sub® electrophoresis tank (Bio-Rad Laboratories, Richmond, USA) filled 
with 1x TPE electrophoresis buffer (0.36 M Tris-HCl; 0.3 M NaH2PO4; 0.1 M EDTA, pH 
7.5). The complexes for both CS-AuNP and CS were prepared as outlined in Table 3.1 in a 
total volume of 10 µl in HBS. A negative control containing Fluc-mRNA (1 µl, 0.25 µg/µl) 
was also included. After the 30-minute hour incubation period and complex formation, 3 µl 
of 6x gel loading buffer [0.25% (w/v) bromophenol blue dye and 40% sucrose] was added to 
all samples. Thereafter, approximately 10 µl of each sample was loaded into separate wells. 
Electrophoresis was then conducted at 50 volts (V) for 30 minutes. The gels were then 
viewed under UV transillumination in a Vacutec Syngene G:Box gel documentation system 
and images were captured using  the  Syngene Gene-Snap programme (Syngene, Cambridge, 
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3.2.2.6.2 Dye displacement/Intercalation assays 
 
3.2.2.6.2.1 Ethidium bromide dye displacement 
The fluorescent based Ethidium Bromide (EtBr) dye displacement assay was also used as 
confirmation of complex formation as well as to determine the extent of condensation of the 
nucleic acid by the respective NP. Fluorescence was measured at an excitation wavelength of 
520 nm and emission wavelength of 600 nm using a Glomax® Multi-detection system 
(Promega Systems, Sunnyvale, USA). Approximately 100 µl of HBS was added to two 
separate wells on a 96 well FluorTrac flat-bottom black microplate. Subsequently, 2 µl of 
EtBr was added to each well, mixed thoroughly and fluorescence measured. This was taken 
as the 0% baseline relative fluorescence reading. Thereafter, 1 µl of Fluc-mRNA (0.25 µg/µl) 
was added to each well and mixed, and fluorescence measured. This reading was taken as 
100% relative fluorescence. Subsequently, 1 µl aliquots of the CS-AuNP solution (0.025 
µg/µl) and the CS solution (0.025 µg/µl) were added separately to each well in a step-wise 
manner, and fluorescent measurements recorded after each addition until a point of inflection 
in fluorescence was achieved. Fluorescence measurements were calculated as relative 
fluorescence (Fr) and plotted using the equation Fr (%) = (Fi – F0) / (Fmax - F0) x 100 where F0 
is the fluorescence intensity of EtBr/HBS mixtures, Fi is the fluorescence intensity at each 
concentration of CS-AuNP or CS and Fmax is the fluorescence intensity of the EtBr/Fluc-
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mRNA mixture. Thereafter, relative fluorescence was plotted against the mass (µg) of CS-
AuNP or CS. 
 
3.2.2.6.2.2 SYBR Green dye displacement 
Further confirmation of complex formation was obtained using the SYBR Green RNA II gel 
stain (10 000× concentrated in DMSO) which is more sensitive and is selective for RNA 
molecules, unlike EtBr. The SYBR Green dye displacement technique employed the same 
protocol and calculations as described previously (3.2.2.6.2.1) with a few modifications. 
Fluorescence was measured at an excitation wavelength of 497 nm and an emission 
wavelength of 520 nm.  Additionally, the baseline relative fluorescence reading of 0% was 
measured by adding 1 µl of the diluted SYBR Green dye to 100 µl of HBS.  
 
3.2.2.7 Nuclease Protection assay 
The level of protection offered by CS-AuNP and CS to the Fluc-mRNA in an environment 
that mimics that of an in vivo system was assessed using the nuclease protection assay. Sub-
optimum, optimum and supra-optimum ratios for CS-AuNP:Fluc-mRNA and CS:Fluc-
mRNA were selected based on the results obtained from the gel retardation assay and 
prepared as outlined below (Table 3.2). The final volume of the complexes was made up to 
10 µl with HBS. The mixtures were incubated at room temperature for 30 minutes to allow 
for the formation of CS-AuNP/CS:Fluc-mRNA complexes. Thereafter, 1 µl of fetal bovine 
serum (FBS) was added to each complex to a final concentration of 10% FBS.  The positive 
control contained Fluc-mRNA (1 µl, 0.25 µg/µl) and the negative control contained Fluc-
mRNA (1 µl, 0.25 µg/µl) treated with FBS. Thereafter, all samples containing FBS were 
incubated at 37C for 4 hours in a water bath (Model 130, Thermo Fischer Scientific Inc., 
Waltham, Massachusetts, USA) to facilitate the nuclease digestion reaction. After the 4-hour 
incubation period, EDTA was added to all samples to a final concentration of 10 mM EDTA, 
to terminate the FBS reaction, followed by the addition of SDS to a final concentration of 
0.5% SDS and a further incubation at 55C for 20 minutes. Thereafter, samples were 




































































CS-AuNP/CS (µg) 0 0 0.075 0.1 0.125 0.075 0.1 0.125 
Fluc-mRNA (µg/µl) 0.25 
 
0.25 0.25 0.25 0.25 0.25 0.25 0.25 
 
3.2.3 In Vitro cell culture studies 
 
3.2.3.1 Cell culture materials and reagents 
Phosphate-buffered saline tablets [PBS, (140 mM NaCl, 10 mM phosphate buffer, 3 mM 
KCl)], 3-[(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] (MTT, Mw: 414.3 
g/mol, C1H1BrNS) and Dimethyl Sulfoxide [DMSO, Mw: 78.13 g/mol, (CH3)2SO] were 
supplied by Merck (Darmstadt, Germany). Research Grade Fetal Bovine Serum (FBS) was 
supplied by Hyclone GE Healthcare (Utah, USA). Sterile Eagle’s Minimum Essential 
Medium (EMEM) with L-glutamine (4.5 g/ml), Penicillin/Streptomycin/Amphotericin B 
(100×) antibiotic mixture [Amphotericin B (25 mcg/ml), NaCl (8.5 mg/l) Potassium penicillin 
(10 000 units/ml), Streptomycin sulphate (10 000 mcg/ml)] and Trypsin-versene-EDTA 
mixture [versene-EDTA (200 mg/l), Trypsin (170 000 U/l)] were supplied by Lonza Bio 
Whittaker (Verviers, Belgium). The luciferase assay kit consisting of the luciferase cell 
culture lysis reagent (5×) [25 mM Tris-phosphate, (pH 7.8), 2 mM dithriothreitol, 2 mM 1,2-
diaminocyclohexane-N,N,N’,N’-tetra-acetic acid, 10% (v/v) glycerol, 1% (v/v) triton X-100], 
luciferase assay reagent (20 mM tricine, 1.1 mM Magnesium carbonate hydroxide, 
pentahydrate, 2.7 mM Magnesium sulphate, 0.1 mM EDTA, 33.3 mM dithriothreitol, 270 
µM coenzyme), Molecular grade ethidium bromide solution (10 mg/ml)  (Mw: 394.31 g/mol, 
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C21H20BrN3) were purchased from Promega (Madison, Wisconsin, USA). Acridine Orange 
hemi (zinc chloride) salt [3,6-Bis(dimethylamino)acridine hydrochloride zinc chloride double 
salt], bicinchoninic acid solution [1% 2,2’-Biquinoline-4,4-dicarboxylic acid disodium salt, 
0.16% Sodium tartrate, 0.4% Sodium hydroxide, 2% Na2CO3.H2O, 0.95% NaHCO3, (pH 
11.25)], Copper (II) sulfate solution [4% (w/v)] and BSA protein standard (1 mg/ml in 0.15 
M NaCl, 0.05% NaN3) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, USA). 
All routine sterile tissue culture plasticware were supplied by Corning Inc., (New York, 
USA). Human embryonic kidney cells (HEK293) were provided by the Anti-Viral Gene 
Therapy Unit, Medical School, University of Witwatersrand. Human epithelial colorectal 
adenocarcinoma cells (Caco-2) were purchased from Highveld Biologicals (Pty) Ltd, Kelvin, 
RSA and the MCF-7 (HTB-22™) breast cancer line was purchased from the American Type 
Culture Collection (ATCC®), Manassas, Virginia, USA. 
 
3.2.3.2 Reconstitution of frozen cells and routine cell culture maintenance 
Aseptic techniques were followed for all processes and all cell culture work conducted in an 
Airvolution Class II Biohazard cabinet. All work surfaces were thoroughly wiped with 70% 
ethanol. Prior to use, all cell culture reagents were warmed to 37°C. Frozen cryogenic vials of 
each cell line were thawed in a 37°C water bath, followed by centrifugation at 3000 rpm for 1 
minute in an Eppendorf centrifuge (Model 5415D, New York, USA). The DMSO-containing 
supernatant was then discarded and the cell pellet resuspended in 1 ml of fresh complete 
medium [EMEM, 10% (v/v) FBS and 1% (v/v) antibiotic mixture]. The cell suspension was 
then transferred to a cell culture flask containing 5 ml of complete medium and incubated at 
37°C for 24 hours in a Steri-cult HEPA class 100 CO2 incubator (Thermo-Electron Co., 
Waltham, Massachusetts, USA).  
Thereafter, the medium in the cell culture flask was replaced with 5 ml of fresh complete 
medium to remove any remaining DMSO which is toxic to cells at a temperature greater than 
4°C. The cells were then allowed to propagate by incubation at 37°C in a 5% CO2 incubator 
and monitored visually on a daily basis using a Nikon TMS inverted light microscope (Nikon 
Co., Tokyo, Japan). The cells were routinely washed with 5 ml of PBS and medium replaced 
every 2-3 days until growth confluency was obtained. Cells were split as desired into flasks 
or multi-well plates for assays. 
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3.2.3.3 Trypsinization of cells and cell counts 
Upon confluency, the spent medium was removed and discarded into a waste bottle. The cells 
were then washed with 5 ml PBS followed by the addition of 1 ml trypsin-versene.  The cells 
were monitored under the inverted microscope to observe the action of the enzyme and the 
“rounding off” of the cells. Thereafter, 2 ml of complete medium was added to the flask to 
inhibit the enzyme reaction. The cell culture flask was then gently tapped against the palm of 
the hand to aid in completely dislodging the cells from the surface. Prior to any experiments, 
a cell count was conducted under the inverted microscope using a haemocytometer slide 
(Marienfield-Superior, Germany). The trypsinized cells were seeded into multi-well plates for 




Following trypsinization, the cells were centrifuged at 3000 rpm for 5 minutes, the 
supernatant discarded and the cell pellet resuspended in 0.9 ml complete medium and 0.1 ml 
of the cryoprotective storage medium (DMSO).  The suspension was then mixed and 1 ml 
aliquots dispensed into respective cryogenic vials which were placed in a Nalgene™ “Mr 
Frosty” Cryo 1°C freezing container (Thermo Fischer Scientific Inc., Waltham, 
Massachusetts, USA) containing isopropanol and frozen at a rate of -1°C per minute to a 
temperature of -70°C in a biofreezer (Nuaire, Lasec laboratory and Scientific Equipment). 
Thereafter, the cryogenic vials were transferred to a cryobox and stored in a biofreezer at -
80°C for short term storage or in liquid nitrogen for long term storage.   
 
3.2.3.5 MTT cytotoxicity assay 
Cells were trypsinized and seeded at a density of 7.8 x 104 cells/well (HEK293), 9.6 x 104 
cells/well (Caco-2) and 2.1 x 105 cells/well (MCF-7) in clear 48-well plates. To allow for 
attachment, cells were incubated at 37°C for 24 hours. Thereafter, all complexes were 
prepared in triplicate as described previously and outlined in table 3.2.  Spent medium was 
removed from each well and replaced with fresh complete medium followed by the addition 
of the complexes to the respective wells. A positive control containing only cells (in 
triplicate) was included. The cells were then incubated at 37°C for 48 hours. Subsequently, 
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the spent medium was removed from each well and replaced with 200 µl of fresh complete 
medium together with 200 µl of MTT reagent (5 mg/ml in PBS) and cells incubated at 37°C 
for 4 hours. Thereafter, the MTT infused medium was removed and 200 µl of DMSO was 
added to solubilize the formazan crystals present (Figure 3.4).  
The plate was then gently shaken and absorbance read at 570 nm in a Mindray MR-96A 
microplate reader (Vacutec, Hamburg, Germany) with DMSO as the blank. Results were 
calculated as cell viability (%) using the following equation: (Abs of treated – Abs of control/ 
Abs of control) x 100%; with the positive control being taken as 100% cell viability.  
 
Figure 3.4: Mechanism depicting the reduction of MTT to formazan by mitochondrial reductase 
present in living cells (Barahuie et al., 2014). 
 
3.2.3.6 Luciferase reporter gene assay 
Transfection efficiency of the complexes was evaluated using the luciferase reporter gene 
assay that measures bioluminescence as a direct correlation of luciferase activity. The 
mechanism of action of the luciferase enzyme is depicted in figure 3.5. 
Cells were seeded at a density of 7.8 x 104 cells/well (HEK.293), 9.6 x 104 cells/well (Caco-
2) and 2.1 x 105 cells/well (MCF-7) in a 48-well clear plate which was then incubated at 370C 
for 24 hours. Thereafter, nanocomplexes (prepared as for cytotoxicity assay, table 3.2) in 
triplicate were added to respective wells that were replenished with fresh complete medium.  
Two controls were set up in triplicate: one containing cells only and the other containing cells 
with naked Fluc-mRNA (0.25 µg/µl). Cells were then incubated at 37°C for 48 hours, after 
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which the spent medium was removed and the cells were rinsed twice with 200 µl of PBS. 
Approximately 80 µl of 1× luciferase cell culture lysis reagent was then added and the plate 
shaken for 15 minutes at 30 rev/min on a STR6 platform shaker (Stuart Scientifc, 
Staffordshire, UK). Thereafter, the cells were scraped from the wells and the cell suspension 
centrifuged at 12000 x g to pellet the cell debris.  
Approximately 20 µl of each cell free supernatant was transferred to individual wells on a 96-
well FluorTrac flat-bottom white microplate (Promega Systems, Sunnyvale, USA), to which 
was added 50 µl of the luciferase assay reagent. This was thoroughly mixed and 
luminescence immediately read in a GloMax® Multi-detection system (Promega Biosystems, 
Sunnyvale, USA), operated by Instinct software and primed with the luciferase assay reagent 
and with the Photo Multiplier Tube (PMT) activated. Protein determination was performed 
on the cell free extracts using the bicinchoninic acid (BCA) assay and readings obtained 
using a Mindray MR-96A microplate reader at 562 nm. All luminescence readings were 
normalized against the protein content and expressed as relative light units per milligram 
protein (RLU/mg protein).  
 
Figure 3.5: Mechanism of the bioluminescence exhibited upon oxidation of the substrate D-Luciferin 
by the luciferase enzyme present in transfected cells (Bai et al., 2015). 
 
3.2.3.7 Acridine Orange/Ethidium Bromide (AO/EB) apoptosis assay 
 Cells were seeded at a density of 1.8 x 106 cells/well (HEK293), 9.6 x 104 cells/well (Caco-
2) and 1.26 x 105 cells/well (MCF-7) in a 48-well clear plate and incubated at 37°C for 24 
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hours. Thereafter, nanocomplexes were prepared, as previously described, in triplicate but 
were based on the optimal ratios obtained from the MTT cytotoxicity (3.2.3.5) and Luciferase 
reporter gene assays (3.2.3.6) as outlined in Table 3.3 below. After 24 hours, the spent 
medium in each well was replaced with fresh complete medium and the complexes added to 
individual wells. The positive control contained cells only. The cells were then incubated at 
37°C for 24 hours, followed by removal of the spent medium and washing of the cells with 
200 μl of PBS. Cells were then stained with 10 μl of the AO/EB dye (0.1 μg/µl acridine 
orange and 0.1 μg/µl Ethidium bromide in PBS) at room temperature for 5 minutes. The stain 
was then removed and the cells washed with 200 μl of PBS. The cells are then viewed for 
apoptotic-induced morphological changes against the control, using an Olympus inverted 
fluorescent microscope (200× magnification) fitted with a CC12 fluorescent camera, an 
excitation filter of 450-490 nm, a barrier filter of 520 nm and Soft Imaging System (SIS) 
software (Olympus Co., Tokyo, Japan). The apoptotic index for each sample was calculated 
using the following equation:                                                                      
Apoptotic index = number of apoptotic cells / total number of cells 
Acridine orange penetrates both the living and dead cells producing green fluorescence 
whereas ethidium bromide produces red fluorescence in cells with altered membranes 
indicating apoptosis. After visual analyses, the cells were scraped into 200 µl of PBS in a 
FluorTrac flat-bottom black microplate and fluorescence measured at an excitation 
wavelength of 520 nm and emission wavelength of 600 nm in the Glomax® Multi-detection 
system. The fluorescence readings were averaged over three replicates (n=3) and reported as 
fluorescent intensity (FI).  
Table 3.3. Preparation of complexes for the AO/EB apoptosis assay. 
Composition of samples CS-AuNP CS 
 





CS-AuNP/CS (µg) 0.125 0.125 






3.2.3.8 Statistical analysis 
All data obtained was calculated as the mean ± standard deviation (±SD n=3) and plotted on 
graphs using Microsoft Excel 2010 (Microsoft, USA). Using the Graphpad Instat Prism 4.0.3 
software, the one-way analysis of variance (ANOVA) test was conducted for multi-group 
comparisons of the calculated means. Thereafter, the Dunnett’s post hoc test was carried out 
for the MTT cytotoxicity assay results and the Tukey-Kramer post hoc test was carried out 
for the Luciferase reporter gene assay results. Statistical significance (P) values determined to 
be less than 0.05 were regarded as significant and represent on the graph as *** p < 0.001, ** 
p < 0.01 and * p < 0.05.  
 
3.3  Results and Discussion 
3.3.1 Characterization of Nanoparticles and Nanocomplexes 
 
3.3.1.1  Chemical analysis 
 
The ICP/OES system is one of the most dominant and standard analytical tools for the 
determination of trace elements in numerous types of samples such as agricultural, food, 
biological, clinical, geological, environmental, water, metals and organic materials (Hou et 
al., 2000). The concentration of the synthesized AuNP was confirmed by ICP against a 
standard Au sample by correlation of the electron signals emitted at each wavelength 
(Appendix A1).  
The frequency of infrared radiation absorbed is characteristic to a molecule and thus may be 
used to identify and confirm the chemical composition of a given sample. FTIR spectroscopy 
confirmed the composition of the AuNP, CS and CS-AuNP solutions (Appendix A2). Citrate-
capped AuNPs exhibited characteristic absorption peaks at 1635.63 cm−1 indicating the 
stretching of the C=O bond of the carboxylic carbonyl group and 3272.20 cm−1 indicating 
the stretching of O-H bonds as compared to previous literature (Chen et al., 2013). The 
spectrum of CS exhibited characteristic absorption peaks at 1028.14 cm–1 and indicates the C-
O stretch vibration, 1508.83 cm–1 for the amide I band which indicates the C=O stretch 
vibration band and 3254.05 cm−1 for the amide A band, indicating the N-H stretch vibration 
as compared to previous literature (Cardenas et al., 2002). In contrast to the AuNP FTIR 
spectrum, the characteristic peaks of the C=O and O-H stretches of the AuNPs increased to 
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1635.14 cm−1 and decreased to 3270.35 cm−1 after functionalisation with CS. These results 
indicate that the reducing ends of the citrate ions formed interactions with the amino groups 
of CS as reported in previous literature (Nivethaa et al., 2012).  
 
3.3.1.2 UV-Vis optical spectrophotometry analysis and dialysis 
Gold nanoparticles display the optical characteristic of surface plasmon resonance (SPR) and 
is defined as the collective oscillation of electrons in the conduction band of the nanoparticles 
in resonance with a specific wavelength of incident light (Doyen et al., 2013). The SPR of 
AuNPs generates a strong absorbance band in the visible region at 520 nm which is also 
accountable for the ruby red colour of the solution and can be measured by UV-Vis 
spectroscopy (Daniel and Didier, 2004).  
UV-vis spectroscopy is a very valuable technique which allows approximation of gold 
nanoparticles size, concentration and aggregation level (Amendola and Meneghetti, 2009). 
The SPR phenomenon is influenced by factors such as size, shape, core charge, solvent, 
surface ligand and temperature (Yeh et al., 2012). The SPR of AuNPs enhances their 
absorption and scattering properties (Radwan and Azzazy, 2009). 
The SPR absorbance of the synthesized AuNPs exhibited a distinct peak at 520 nm (Figure 
3.6) correlating with literature and confirming the successful synthesis of citrate-capped 
AuNPs.  Upon functionalisation with CS (Figure 3.6), the SPR absorbance experienced a red-
shift to 530 nm, indicating a change in the nanoparticles causing an alteration of the normal 
local refractive index of the AuNPs. This red-shift has previously been reported for the 
functionalisation of AuNPs with CS (Mohd and Johan, 2014; Wu et al., 2009 and Bhumkar et 
al, 2009). In addition, this red-shift was also observed upon complex formation of CS-AuNP 
with Fluc-mRNA, exhibiting an SPR absorbance at 540 nm (Figure 3.7). The absorbance of 
the CS-AuNP recorded after dialysis further indicated the successful removal of the unbound 
CS. The percentage of bound CS was determined to be 87%, indicating excellent binding 





Figure 3.6: UV-Vis spectrum of AuNP, CS-AuNP before dialysis and CS-AuNP after dialysis 











3.3.1.3 Qualitative Ninhydrin test for amine groups 
 
The ninhydrin test has been well-established and extensively utilized for amino acid analysis 
over the years (Prochazkova et al., 1999). The principle of the ninhydrin reaction relies on the 
reaction of free primary amines with the ninhydrin reagent to produce a blue-purple coloured 
complex, a diketohydrindylidene-diketohydrindamine known as Ruhemann’s purple and is 
indicative of a positive reaction. (Lago et al., 2011). In theory, based on the structure of CS 
which is a linear polymer of (1,4)-linked 2-amino-deoxy-β-D-glucan, the reaction with 
ninhydrin should yield a positive result, as obtained for the CS-AuNP (Figure 3.8) indicating 
the presence of CS and the successful functionalisation of AuNP with CS. 
 
 
Figure 3.8: Image of the light purple CS-AuNP solution after the ninhydrin test indicating a positive 
reaction. 
 
3.3.1.4 Transmission electron microscopy 
 
Transmission electron microscopy (TEM) is a vital characterization technique to image the 
AuNPs which are presented as dark spheres (Figure 3.9). TEM is used to verify the 
morphology and size of the AuNPs and acts by transmitting a focussed beam of electrons 
through the sample, forming a high-resolution image (Lee, 2011). TEM micrographs 
displayed AuNPs, CS-AuNP and CS-AuNP:Fluc-mRNA complexes as homogenous, 
spherical and smooth particles that were well-dispersed (Figure 3.9), similar to previously 
reported studies (Verma et al, 2014; Kumar et al., 2011; Philip, 2008 and Kimling et al., 
2006). The AuNPs in each micrograph were displayed as dark spheres indicating that the 
Au3+ ions were reduced to neutral gold atoms which nucleated and grew to produce dark, red 
spheres (Thanh et al., 2014). 
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The excellent dispersion of the AuNPs may be attributed to the electrostatic stabilization due 
to the citrate capping, repelling the AuNP atoms from each other (Polte, 2015). Upon 
functionalisation with CS (Figure 3.9 B), the nanospheres adopted chain-like structures which 
may have attributed to the red-shift observed in the UV-Vis spectroscopy analysis. It has 
been proposed that the morphology and size of CS functionalised AuNPs are dependent upon 
the varying chain length of CS and directly proportional to the amount of AuNPs absorbed 
along the chain (Narayanan and Sivakumar, 2014). In addition to electrostatic stabilization, 
CS provides steric stabilization to the AuNPs, preventing aggregation (Polte, 2015). Upon 
CS-AuNP and Fluc-mRNA complexation (Figure 3.9 C), the formation of aggregates can be 
seen due to the condensation of Fluc-mRNA and the overall interactions of the citrate-capped 
AuNPs, CS and Fluc-mRNA. 
        
Figure 3.9: Transmission electron micrographs depicting the morphology of (A) AuNPs, (B) CS-
AuNP and (C) CS-AuNP:Fluc-mRNA at a magnification of 50 000×. 
 
3.3.1.5 Nanoparticle tracking analysis (NTA) 
Among the various properties of AuNPs which require complete characterisation, the size, 
quality and stability of their dispersion have a profound effect on their interactions with 
organisms and the environment (Hole et al., 2013). It has been reported that AuNP response 
to the surrounding environment is dependent on size (Jiang et al., 2008). This is attributed to 
their large surface area which interacts with the surrounding matrix and may influence their 
reactivity with targets in the cells (Lison and Huaux, 2011). Recently, Nanoparticle tracking 
analysis (NTA) has been utilized to determine the size, zeta potential, colloidal stability and 
distribution of AuNPs in liquids (Wagner et al., 2014).  
NTA is based on the illumination of freely diffusing particles by use of an intense laser light 
analysis of monochrome images used to track the Brownian motion and size distribution of 
(A) (B) (C) 
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the particles which is estimated by the Stokes-Einstein equation (Wagner et al., 2014). The 
NTA analysis (Table 3.4 and Appendix B) determined the average size of AuNPs in solution 
to be 65.9 +/- 9.8 nm over a concentration of 2.55e+008 +/- 1.69e+006 particles/ml. Upon 
functionalisation, the average size of CS-AuNPs increased to 69.6 +/- 15.2 nm over a 
concentration of 2.28e+008 +/- 5.38e+006 particles/ml, which may be due to the 
functionalization and the formation of chain-like structures as seen in the TEM micrographs.  
Upon CS-AuNP and Fluc-mRNA complexation, the size of CS-AuNP:Fluc-mRNA particles 
increased to  95.0 +/- 9.9 nm over a concentration of 7.43e+008 +/- 1.99e+006 particles/ml, 
indicating the formation of aggregates due to the condensation of Fluc-mRNA and the overall 
interactions of the AuNPs, CS and Fluc-mRNA. All nanoparticle formulations displayed 
sizes below 100 nm, making them suitable for gene delivery purposes. 
Apart from size, surface chemistry is predominantly important in inhibiting uncontrolled 
aggregation and is directly related to the transfection efficiency of nanoparticles (Son et al., 
2000). Zeta potential analysis is a technique that involves the measurement of potential 
differences between the surface and the slipping plane of the stationary fluid layer of a 
nanoparticle (Arjmandi et al., 2012). This measurement is used to quantify surface charge in 
a buffer with a fixed composition, pH concentration and ionic strength.  
In general, an excellent zeta potential (greater than 25 mV or -25 mV) indicates the formation 
of stable nanoparticles and as the zeta potential approaches the point of zero charge, the 
attraction between nanoparticles surpasses the repulsive forces between the nanoparticles 
causing aggregation (Ivanov, 2011). Thus, zeta potential analysis is important for determining 
nanoparticle surface chemistry and long-term stability.  
From the zeta potential analysis (Table 3.4 and Appendix B) it was observed that the AuNPs 
by themselves did not have excellent colloidal stability as their surface charge was 
determined to be -7.3 +/- 1.6 mV. However, upon functionalisation with CS, the zeta 
potential increased to 55.5 +/- 1.2 mV which shows excellent colloidal stability of the 
nanoparticles. Similar measurements based on CS functionalisation of AuNPs have also been 
reported in previous studies (Boyles et al., 2015 and Bhumkar et al., 2007). This observation 
shows that CS with its high positive charge density improved the surface chemistry 
characteristics of the AuNPs, resulting in steric stabilization of the AuNPs preventing 
unwelcome aggregation. Upon CS-AuNP and Fluc-mRNA complexation, the zeta () 
potential decreased to 25.9 +/- 0.5 mV which also indicated a relatively stable nanocomplex. 
63 
 
This may be attributed to the electrostatic condensation of the negatively charged Fluc-
mRNA by the positively charged CS-AuNP particles. In addition, TEM micrographs 
indicated slight aggregation which will affect the zeta potential. Overall, the functionalized 
and complexed nanoparticles were proven to be stable and suitable for gene delivery studies. 
Table 3.4 Size, zeta potential and concentration of the nanoparticle solutions obtained from 
nanoparticle tracking and zeta potential analysis. 







AuNP 65.9 +/- 9.8  -7.3 +/- 1.6  2.55e+008 +/- 1.69e+006  
CS-AuNP 69.6 +/- 15.2  55.5 +/- 1.2  2.28e+008 +/- 5.38e+006  
CS-AuNP:Fluc-mRNA 95.0 +/- 9.9  25.9 +/- 0.5  7.43e+008 +/- 1.99e+006  
 
 
3.3.2 Assessment of CS and CS-AuNP binding to Fluc-mRNA 
 
3.3.2.1 Gel retardation assay  
 
The gel retardation or band shift assay was conducted to determine the minimum 
concentration of CS-AuNP and CS required to fully bind 0.25 µg of Fluc-mRNA (optimal 
binding ratio). Traditionally, agarose gel electrophoresis is used for the separation of 
biomolecules such as nucleic acids and proteins and has also recently been employed for the 
separation of metal nanoparticles such as AuNPs (Hasenoehrl et al., 2012). This assay has 
been extensively applied for the study of protein-nucleic acid interactions but may be adapted 
for the use of studying various nucleic acid conjugate interactions (Hellman and Fried, 2009). 
The principle of agarose gel electrophoresis separation and electrophoretic mobility is based 
on charge, size and shape of the migrating biomolecule (Laniel et al., 2001). However, in 
addition to separation, this assay allows for the study of the electrostatic binding ability of 
CS-AuNP and CS (positively charged) to entirely neutralize the Fluc-mRNA (negatively 
charged), producing an electroneutral complex which will be restricted in electrophoretic 
mobility (Huang et al., 1998). 
If Fluc-mRNA present is not completely bound to the CS-AuNP/CS it will be free to migrate 
into the gel from the cathode to the anode based on general agarose gel electrophoresis 
principles. However, if Fluc-mRNA is completely bound to the Cs-AuNP it will not able to 
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migrate into the gel due to the formation of an electroneutral complex. For transfection 
purposes, it is imperative to determine the concentration of CS-AuNP and CS required to 
fully bind the Fluc-mRNA. 
Both CS-AuNP (Figure 3.10 A) and CS (Figure 3.10 B) at varying concentrations, were 
assessed for their ability to electrostatically bind to the Fluc-mRNA (0.25 µg/µl) in lanes 2-8 
as outlined in Table 3.1. In both assessments, lane 1 served as a control containing 0.25 µg/µl 
of Fluc-mRNA. The endpoint or optimal ratio for each assessment is indicated by a white 
arrow wherein electroneutrality was achieved. It was observed that the amount of CS-AuNP 
and CS complexes retained in the wells increased with increasing CS-AuNP and CS 
concentrations, respectively.  
Electroneutrality and optimal binding ratios were achieved for CS-AuNP:Fluc-mRNA 
(Figure 3.10 A) at a ratio of 0.4:1 (w/w) (lane 5) and for CS:Fluc-mRNA (Figure 3.10 B) at a 
ratio of 0.4:1 (w/w) (lane 5). The efficient binding of Fluc-mRNA by CS-AuNP and CS at 
low concentrations may be attributed to its high positive charge density. 
 
                  
Figure 3.10: Gel retardation study of (A) CS-AuNP:Fluc-mRNA and (B) CS:Fluc-mRNA complexes. 
Incubation mixtures (10 µl) in 20 mM HEPES, 150 mM NaCl (pH 7.5) contained varying amounts of 
(A) CS-AuNP and, (B) CS in lanes 1–8 (0, 0.025, 0.05, 0.075, 0.1, 0.125, 0.15, 0.175 µg) and Fluc-
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3.3.2.2  Dye Displacement/Intercalation assays  
Fluorescent intercalation displacement assays have been used extensively to examine 
interactions and define the binding affinities of small ligands (Sau et al., 2012). These 
intercalation assays are based on the quenching of the fluorescence as a result of the 
displacement of mRNA-bound dye by mRNA-binding compounds such as CS-AuNP and CS 
as used in this study. In both assays (Figure 3.11 and 3.12), it was observed that both the CS-
AuNP and CS solutions were able to successfully displace the dye from the Fluc-mRNA.  
It was observed that a lower concentration of CS was required to fully bind the Fluc-mRNA 
in comparison to CS-AuNP which may be attributed to the lack of positive charges available 
on the surface of the AuNPs after binding to CS. The endpoints or points of inflection 
(indicated by arrows) specify the concentration of CS-AuNP or CS at which the Fluc-mRNA 
was fully bound. In both methods (Figure 3.11-3.12), a step-wise decrease in fluorescence 
was observed as the NPs bound to the mRNA, displacing the bound dye.  
The concentration required to fully bind the Fluc-mRNA was 0.325 µg for CS-AuNP and 
0.255 µg for CS which was higher than those obtained from the gel retardation assay. This 
may be due to the mechanism of action of EtBr as its tricyclic phenanthridine ring interacts 
with the base pairs of the hydrophobic interior of double-stranded DNA through Van der 
Waals forces to produce fluorescence (Banerjee et al., 2014). This technique has previously 
been reported on the study of AuNP-DNA conjugates and has proven successful (Jang et al., 
2009). However, it has not been reported for the study of AuNP-mRNA conjugates. mRNA 
folds back on itself to produce local base pairing for intercalation with EtBr, hence the 
variation in results. Furthermore, it is possible that the EtBr method did not provide optimal 
parameters for this study while the SYBR Green method is regarded as having specificity 
towards intercalation of RNA (Siddiqui et al., 2013).  
The concentration required to fully bind the Fluc-mRNA was 0.15 µg for CS-AuNP and 
0.125 µg for CS in the SYBR Green method. These values correlated with those obtained 
from the gel retardation assay, thus proving the accuracy of this technique and optimization 




Figure 3.11: Comparison of relative fluorescence between the CS-AuNP and CS complexes using the 




Figure 3.12: Comparison of the relative fluorescence between CS-AuNP and CS complexes using the 
SYBR Green intercalation assay. 
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3.3.3 Nuclease Protection assay 
 
The efficient delivery of nucleic acids is dependent on factors associated with the vehicle of 
choice such as physiochemical properties, cellular interaction, target specificity and 
transfection efficiency. However, the physiological environment in vivo plays a crucial role in 
gene delivery and expression. Serum nucleases, present in biological fluids, are a great 
obstacle in gene delivery due to the risk of nucleic acid degradation. For effective expression, 
nucleic acids carried by the delivery vehicles must be protected against degradation by serum 
nucleases (Quong and Neufeld, 1998). Some studies have highlighted the instability of 
mRNA under physiological conditions, enforcing the need for an effective delivery system 
for safe mRNA delivery. AuNPs have shown potential to be effective delivery vectors (Kim 
et al., 2015) but the need for their optimization to suit these protective functions are yet to be 
fully recognised.  
To examine the protection offered by our nanoparticles to the mRNA, a nuclease digestion 
study was conducted which mimics the physiological environment in biological fluids and 
involves the treatment of nanocomplexes with fetal bovine serum (FBS) containing 
nucleases. Using binding ratios obtained from the gel retardation assay, three ratios (sub-
optimum, optimum and supra-optimum) were selected for assessment (Figure 3.13). The 
positive control (C1) contained undigested Fluc-mRNA (0.25 µg) presented as a single 
distinctive bright band while the negative control (C2) containing FBS-digested Fluc-mRNA 
(0.25 µg) showed degradation of the Fluc-mRNA, indicating complete digestion. All 
complexes were treated with FBS to facilitate the digestion of any unprotected Fluc-mRNA 
and thereafter the nuclease reaction was terminated by treatment with EDTA. Subsequently, 
the complexes were treated with SDS to facilitate the release of the Fluc-mRNA from the 
nanocomplex. Fluc-mRNA which has been digested by the FBS will migrate into the gel and 
appear as a smear after agarose gel electrophoresis similar to the negative control (C2) 
whereas undigested Fluc-mRNA will appear as a distinct band similar to the positive control 
(C1). 
Lanes 1-2 (Figure 3.13) showed partial digestion of the mRNA, indicating that the amount of 
CS-AuNP at the (sub-optimum and optimum) ratios provided some but not total protection of 
the Fluc-mRNA. This may be attributed to the weak compaction, probably due to the lack of 
binding sites available on the surface of CS-AuNPs that are dependent on the electrostatic 
interactions between the AuNPs and CS.  
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However, at the supra-optimum ratio (lane 3) no digestion was observed, indicating complete 
protection of Fluc-mRNA by CS-AuNPs at the ratio of 1:0.5. CS offered complete protection 
of Fluc-mRNA at the sub-optimum (1:0.3) and optimum ratios (1:0.4) as no digestion of 
Fluc-mRNA was observed (Lanes 4-5, Figure 3.13).  However, at the supra-optimum ratio 
(1:0.5) partial digestion was observed and this may be due to looser binding of the Fluc-
mRNA at a higher ratio and possible aggregation of the CS particles. In comparison, CS 
exhibited enhanced protection ability over Fluc-mRNA compared to CS-AuNP. Furthermore, 
the density of charges available on the surface of a particle plays a factor in binding and thus 
protection. Therefore, it can be assumed that the CS-AuNPs contained fewer binding sites for 
the mRNA than CS alone due to functionalisation. Hence, CS-AuNP seems to be most 




Figure 3.13: Nuclease digestion of CS-AuNP:Fluc-mRNA and CS:Fluc-mRNA complexes. 
Incubation mixtures (10 µl) in 20 mM HEPES, 150 mM NaCl (pH 7.5) contained a constant amount 
of Fluc-mRNA (0.25 µg) in all lanes and varying amounts of CS-AuNP, lanes 1-3 (0.075, 0.1, 0.125 
µg) and CS, lanes 4-6 (0.075, 0.1, 0.125 µg). C1 contained undigested Fluc-mRNA and C2 contained 
FBS-digested Fluc-mRNA. 
 
3.3.4 In Vitro cell culture studies 
 
3.3.4.1 Reconstitution and cell culture maintenance 
 
All cell lines were successfully propagated in complete medium (EMEM, 10% FBS and 1% 
antibiotic). All cells were monitored with an inverted microscope and images captured under 
phase contrast microscopy.  
 C1   C2    1     2     3     4     5     6 
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HEK293 cells (Figure 3.14 A) showed an epithelial fibroblast morphology, Caco-2 cells 
(Figure 3.14 B) exhibited a polarized epithelial morphology and MCF-7 cells exhibited a 
dome-like morphology (Figure 3.14 C). 
      
Figure 3.14: Images of confluent cell lines (A) HEK293, (B) Caco-2 and (C) MCF-7 using phase 
contrast microscopy at a 10 000× magnification. 
 
3.3.4.2 MTT cytotoxicity assay 
 
The wide applications of AuNPs have raised concerns on its impact on health due to long 
term exposure. Hence, it is important to evaluate its toxicological implications first in vitro 
(Chueh et al., 2014). The MTT cytotoxicity assay has been termed the ‘‘gold standard’’ 
colorimetric assay for cytotoxicity and is based on the measurement of mitochondrial 
enzymatic activity (Alkilany and Murphy, 2010). This assay is based on the principle that 
viable cells possess an active metabolism which will convert MTT into formazan, an 
insoluble purple coloured product (Marquis et al., 2009) while dead cells are incapable of 
making this conversion. Hence, this method serves as a useful indicator of the cytotoxic 
effects inferred by complexes. For all cell lines, a control consisted of cells only (without 
treatment to the complexes) and was taken as 100% cell viability. For the HEK293 cell line 
(Figure 3.15 A), a general trend was seen wherein the cell viability (%) increased as the ratio 
of CS and CS-AuNP to Fluc-mRNA increased. Maximum cell viability of 70% and 60% was 
observed at the supra-optimal ratio (ratio 3) for both CS and CS-AuNP, respectively.  
A similar observation was reported in a study by Ramezani et al., 2014 where scanning 
electron microscopy (SEM) further indicated that the surface of CS-AuNPs was moderately 
(A) (B) (C) 
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rough and porous and therefore can be assumed to interact well with the cell membrane due 
to similar surface characteristics. For the Caco-2 cell line (Figure 3.15 B), the cell viability 
increased as the ratio of CS to Fluc-mRNA increased but the opposite occurred when the 
ratio of CS-AuNP to Fluc-mRNA increased. Cell viability of 96% and 81% was observed at 
the supra-optimal ratio (ratio 3) for CS and the sub-optimal ratio (ratio 1) for CS-AuNP, 
respectively. In the MCF-7 cell line (Figure 3.15 C), the cell viability (%) decreased as the 
ratio of CS to Fluc-mRNA increased but increased as the CS-AuNP to Fluc-mRNA ratio 
increased. Maximum cell viability of 97% and 81% was observed at the sub-optimal ratio 
(ratio 1) for CS and the optimal ratio for CS-AuNPs (ratio 2), respectively. Researchers have 
shown that in the MCF-7 cells an increase of AuNP concentration resulted in a decrease of 
cell viability (Selim and Hendi, 2012). In general, the cell viability results show that 
treatment with these complexes are concentration or dose dependent and cell type specific. 
Overall, both nanocomplexes performed similarly in all cell lines with cell viability over 50% 
at all ratios. 
Cationic nanoparticles possess the ability to interact with the cellular membrane which is 
negatively charged and therefore resulting in membrane disruption (Goodman et al., 2004). 
Further studies have shown that cationic AuNPs can alter the mitochondrial membrane 
potential resulting in oxidative stress (Yah, 2013). Their interaction may be attributed to the 
zeta potential of the nanoparticle surface. For the CS-AuNP:Fluc-mRNA complex, the zeta 
potential was 25.9 +/- 0.5 mV and may have resulted in strong electrostatic binding with the 
cell membrane, resulting in membrane destruction and cytotoxicity. It has also been reported 
that cytotoxicity is size-dependent. Larger nanoparticles have a high surface area to volume 
ratio which provides platforms for an increase in surface particle activity (Van Doren and 
Temmerman, 2011). Although the size of the CS-AuNP:Fluc-mRNA complex was 95.0 +/- 
9.9 nm which is not very large, they may still be susceptible to various surface particle 
activities. In addition, the size range of nanoparticles was similar to that of proteins and small 
viruses which would trigger the immune system resulting in induced immunotoxicity 
(Dobrovolskaia and McNeil, 2007). In vitro studies require the use of growth media which 
contain serum proteins, essential amino acids, vitamins, electrolytes, antibiotics and trace 
metals which could interact with the nanoparticles, altering their physiochemical properties 
such as size, surface charge, surface chemistry and aggregation state (Alkilany and Murphy, 
2010). The high ionic strength and the presence of electrolytes in the growth media can result 
71 
 
in nanoparticle aggregation leading to disruption of the cell (Vesaratchano et al., 2007). 
Aggregation was noted for the CS-AuNP:mRNA in the TEM analysis (Figure 3.9 C). 
       
 
Figure 3.15: MTT cytotoxicity assay of complexes in cell lines: (A) HEK293, (B) Caco-2 and (C) 
MCF-7. Data represented as means ± SD (n=3), * p<0.05, **p<0.01 and **p<0.001 were considered 






3.3.4.3 Luciferase reporter gene assay 
AuNPs are emerging as attractive synthetic vehicles for nucleic acid delivery due to their ease 
of control in terms of size and surface functionality, allowing modulation of cytotoxicity and 
bio-distribution (Ding et al., 2014). In the hope of developing a highly efficient gene carrier, 
we have functionalised AuNPs with CS and evaluated their transfection efficiency using the 
luciferase reporter gene assay. Gene expression is commonly studied in cell biology using 
genetic reporter assays (Allard and Kopish, 2008). The firefly (Photinus pyralis) luciferase of 
16 kDa, a monomeric enzyme, is an extensively utilized reporter (Fan and Wood, 2006). The 
luciferase reporter gene expression assay is a highly sensitive and rapid assay which allows 
immediate measurement of reporter activity after translation as the resulting protein does not 
require post-translational processing (Allard and Kopish, 2008). The reaction is ATP-
dependent in which the luciferase enzyme catalyses the conversion of beetle luciferin 
(substrate) to an enzyme-bound intermediate, luciferyl-AMP.  
This intermediate then reacts with oxygen to generate the final product oxyluciferin in a high-
energy state. A yellow-green light is produced by the subsequent energy transition to the 
ground state and this bioluminescence is measured as relative light units (RLU) at 560 nm. 
The RLU measurements are usually normalized against its corresponding soluble protein 
content in the cell lysates which we determined using the BCA assay. Following the 
incubation of complexes with the cells, the transfection efficiency of the complexes 
containing the luciferase encoded mRNA (Fluc-mRNA) was evaluated by directly correlating 
the luciferase activity (RLU/mg protein) produced by each complex in each cell line.  
For all cell lines, two controls, cells only and cells treated with naked Fluc-mRNA (0.25 
µg/µl) were used. In all cell lines the best transgene activity was observed at the sub-optimal 
ratios (ratio 1) for both the CS and CS-AuNP:mRNA complexes ( Figures 3.16 A-C). 
Maximum luciferase activity for the CS and CS-AuNP:mRNA complexes  were 3.3 x 105 and 
3.8 x 105 RLU/mg protein in the HEK293 cell line (Figure 3.16 A), 4.6 x 105 and 5.3 x 105 
RLU/mg protein in the Caco-2 cell line (Figure 3.16 B), and 4.2 x 103 and 6.6 x 103 RLU/mg 
protein in the MCF-7 cell line (Figure 3.16 C). In all cell lines, a general trend was seen 
wherein the luciferase activity decreased as the ratio of CS and CS-AuNP to Fluc-mRNA 




This observation may be attributed to the high compaction and restricted release of Fluc-
mRNA which is due to the high binding efficiency of CS and CS-AuNP, as established by the 
band shift, dye displacement assays and TEM micrographs which further indicated the 
formation of nano-aggregates. As expected, luciferase activity in comparison to the controls 
was significant, highlighting the importance of the nanovector system. Overall, CS-
AuNP:Fluc-mRNA complexes displayed higher trangene activity than CS:Fluc-mRNA 
complexes, indicating that the transfection efficiency of CS was improved by its combination 
with the AuNPs. The transfection and binding efficiency of CS with nucleic acids are linearly 
correlated with its molecular mass which may result in inferior transfection efficiency (Zhou 
et al., 2008).  
AuNPs have been reported to be taken up voluntarily by cells with their intracellular uptake 
and distribution being dependent on characteristics such as zeta potential, surface 
modification, shape and size (Huefner et al., 2014). Experimental procedures and their 
parameters such as concentration and exposure time also influence their uptake and 
distribution (Mironava et al., 2010). Furthermore, the differences in cell types greatly 
influence the functioning and processing of AuNPs (Doane and Burda, 2012). The 
synthesized CS-AuNP properties such as excellent zeta potential, ability to protect the Fluc-
mRNA and inherent low cytotoxicity all contributed in enhancing the transfection efficiency 








Figure 3.16: Luciferase gene expression activity of complexes measured in RLU/mg protein assayed 
in cell lines: (A) HEK293, (B) Caco-2 and (C) MCF-7. Data represented as mean ± SD (n=3), * 




3.3.4.4 Acridine Orange/Ethidium Bromide (AO/EB) apoptosis assay 
Nanoparticles can elicit adverse effects such as organelle or DNA damage, oxidative stress 
and apoptosis at the cellular level by interacting with vital cell components such as the 
membrane, mitochondria or nucleus (Mironava et al., 2010). Apoptosis is a type of 
programmed cell death that is genetically regulated to control the development of tissues and 
multi-cellular organisms by eliminating physiologically defective, damaged and abnormal 
cells (Liu et al., 2015), hence an effective defence mechanism of the body to kill tumour 
cells. However, cancer is known to inhibit normal cellular processes causing a defect of this 
mechanism. Chemotherapeutics acts by destroying tumour cells and restraining their 
proliferation mainly by promoting apoptosis (Yamamoto et al., 1999). In contrast, the 
efficacy of gene therapy is measured by the vectors’ ability to detect cancer cells and 
selectively repairing damaged genes triggering apoptosis.  
Apoptosis is morphologically characterized by a change in the refractive index of the cell, 
cytoplasmic shrinkage, nuclear condensation and lack of preserving phospholipid asymmetry 
(Pan et al., 2012). The cell membrane forms protrusions which eventually separate from the 
cells to form apoptotic bodies. In addition, the mitochondrial outer membrane forms pores 
which results in a loss of its electrochemical gradient, allowing the leaking of substances into 
the cytoplasm without evoking inflammatory responses. The dying cells and apoptotic bodies 
are then phagocytosed by adjacent cells or macrophages.  In contrast, necrosis is 
morphologically characterized by the swelling of the cytoplasm and mitochondria in the cell 
leading to lysis, affecting the adjacent cells and evoking inflammatory responses (Pan et al., 
2012). The remains of the necrotic cells are then phagocytosed by macrophages.  
To determine the mechanism of cell death due to exposure to the formulated nanocomplexes, 
the apoptosis assay using the AO/EB dual staining method and phase-contrast microscopy 
was employed. The fluorescence intensity of AO/EB in cells was further measured for each 
complex in each cell line. The amount of fluorescence generated is proportional to the 
number of apoptotic cells present. The acridine orange/ethidium bromide (AO/EB) dual 
fluorescence staining coupled with visualization with a fluorescence microscope is a useful 
technique to identify apoptosis-associated changes in cells and accurately distinguish cells at 
different stages of apoptosis (Gherghi et al., 2003). 
Acridine orange acts by permeating the cell and causes the cells to fluoresce green. 
Thereafter, cells which have lost their cytoplasmic membrane integrity selectively take up the 
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ethidium bromide stain and cause the nucleus to fluoresce red (Liu et al., 2015).  The nucleus 
of live cells fluoresces green, apoptotic cells have fragmented chromatin fluoresce red and 
necrotic cells orange (Ribble et al., 2005). All control cells fluoresced green, indicating the 
absence of apoptosis and necrosis (Figure 3.17). The number of apoptotic cells after 
treatment with the CS-AuNP:Fluc-mRNA complex was far greater than that of the CS:Fluc-
mRNA complex, indicating the ability of the CS-AuNP:Fluc-mRNA to induce apoptosis. The 
distinct morphological characteristics of red apoptotic cells were seen and included cellular 
shrinking and blebbing (labelled as ‘A’ in figure 3.17) and orange necrotic cells which 
showed swelling (labelled as ‘N’ in figure 3.17).  
The apoptotic index (Table 3.5) for the CS:Fluc-mRNA complex was 0.05, 0.24 and 0.14, 
while the CS-AuNP:Fluc-mRNA complex apoptotic index (Table 3.4) was 0.06, 0.39 and 
0.20 in the HEK293, Caco-2 and MCF-7 cell lines, respectively. These values directly 
correlated to the fluorescent intensity (Figure 3.18) measurements. The greater apoptotic 
index for the CS-AuNP:Fluc-mRNA complex indicates that the normal cellular apoptosis 
defence mechanism was restored upon treatment with this complex and may be correlated 
with their excellent transfection efficiency and level of cytotoxicity.  
It has previously been reported that an increase in size, concentration and exposure time of 
cells to AuNPs results in a higher percentage of cells undergoing apoptosis (Mironava et al., 
2010). Additionally, AuNPs show cell-type specificity for induction of apoptosis as seen 
between the HEK293, Caco-2 and MCF-7 cell lines with the highest apoptotic index values 
seen in the Caco-2 cell line. Previous studies have reported apoptosis induction in melanoma, 
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Figure 3.17: Fluorescence images obtained from the AO/EB apoptosis assay on HEK293, Caco-2 and 








Table 3.5. Apoptotic index values for each complex on each cell line.  
 
Figure 3.18: Fluorescence intensity (FI) of cell lines HEK293, Caco-2 and MCF-7 with and without 






























































































The design and successful synthesis of CS functionalised AuNP-based gene carriers has been 
shown to significantly influence transgene expression in the three cell lines tested. These 
nanocomplexes were able to bind and compact Fluc-mRNA at low concentrations as 
evidenced from the gel retardation and florescence-based dye displacement assays. Their 
favourable SPR absorption, spherical morphology, small size for cellular uptake, colloidal 
stability, low cytotoxicity and significant reporter gene expression augur well for future in 
vivo studies.  Furthermore, these nanocomplexes afforded protection to the mRNA against 
nucleases, facilitating safe delivery of the cargo and were able to induce apoptosis, more so in 
the cancer cell lines (Caco-2 and MCF-7) than in the normal HEK293 cell line. Preliminary 
results indicate that these CS-AuNPs have the potential to be effective gene delivery vectors, 
especially for cancer treatment.  
Since cytotoxicity, transfection efficiency and apoptosis induction are highly dependent on 
the formulation characteristics of the nanoparticles, the physiological environment and the 
type of cells, future studies will have to take this into consideration. It is recommended that 
formulations of the CS-AuNPs of various concentrations, sizes, shapes and surface charge be 
prepared with the addition of the steric stabilizing polymer, polyethyleneycol (PEG) and 
suitable targeting ligands. Furthermore, studies of different environmental parameters such as 
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Gold nanoparticles (AuNPs) have entrenched themselves in nanomedicine, providing a multi-
platform scaffold for biomedical applications such as the delivery of a variety of 
biomolecules due to their unique physical, chemical and optical properties. In addition, 
AuNPs are low in toxicity, biocompatible and are easily manipulated to control size, shape, 
stability, dispersity, surface composition and charge. AuNPs have shown proven applicability 
as gene therapy vehicles for the treatment of heterogenous diseases such as cancer. For many 
years, plasmid DNA (pDNA) has been the nucleic acid of choice for gene therapy studies. 
However, its use is associated with many limitations such as inefficient intracellular 
trafficking and nuclear entry of genes. As an attractive alternative are mRNA molecules that 
possess the ability to overcome most of these barriers. In this study, we exploit the above 
mentioned desirable properties of mRNA using poly-l-lysine (PLL) functionalised AuNPs 
(PLL-AuNPs) as delivery vehicles for mRNA and assess the level of transgene expression in 
three human cell lines: embryonic kidney (HEK293), colorectal adenocarcinoma (Caco-2), 
and breast adenocarcinoma (MCF-7). AuNPs were synthesized using established protocols 
and functionalised with PLL. All nanoparticles (AuNPs and PLL-AuNPs) and the 
nanocomplexes (PLL-AuNP:Fluc-mRNA) were characterized using UV-Vis 
spectrophotometry, Transmission Electron Microscopy (TEM) and Nanoparticle Tracking 
Analysis (NTA). PLL-AuNP:Fluc-mRNA binding, compaction and stability were evaluated 
using the gel retardation, dye displacement and nuclease protection assays, respectively. The 
levels of cytotoxicity and gene expression in vitro were determined using the MTT and 
luciferase reporter gene assays, respectively. The mechanism for the cytotoxicity was 
ascertained using the AO/EB dual apoptosis assay. PLL:Fluc-mRNA and PLL-AuNP:Fluc-
mRNA nanocomplexes were assayed for comparative analysis. Results indicate that PLL-
AuNPs and their nanocomplexes display appropriate and desirable properties such as small 
size (PLL-AuNP: 90.4 nm, nanocomplexes: 89.4 nm), colloidal stability (zeta potential: PLL-
AuNP: -5.3 mV, nanocomplexes: -97.1 mV), excellent binding, low cytotoxicity (<40%), and 
significant transgene expression. In addition, PLL-AuNPs proved to be more efficient than 
the PLL polymer itself, indicating that AuNPs improve PLL’s biological activity. Overall, 
these results favour the use of PLL-AuNPs as potential vehicles for the delivery of mRNA in 
gene therapy studies. 
Keywords: biomedical, cancer, cytotoxicity, Fluc-mRNA, gene expression, gold 
nanoparticles, immunotherapy, poly-l-lysine 
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4.1  Introduction 
Cancer is one of the most difficult diseases to treat and this global burden has resulted in 
increased efforts towards determining the underlying genetic processes contributing to the 
development of malignancies and tumorigenesis. Many of these genetic processes have been 
altered by various risk factors such as exposure to certain physical and chemical agents, 
radiation, improper diet and exercise, infection, inadequate hormone levels and inherited 
genetic defects (Cancer Association of South Africa, 2016). The past decade has seen an 
explosion in information on tumor biology leading to a variety of therapeutic methods. In this 
regard, prevention and treatment strategies such as chemotherapy, surgery and radiation have 
since been developed and implemented. However, these interventions are employed to kill off 
malignant cells and generally just lead to prolonged survival times. In addition, these 
treatments suffer from a lack of target cell specificity, development of multi-drug resistance, 
poor drug penetration of cancer cells and unbearable side-effects for the patients 
(Sivaramakrishnan et al., 2014).  
Recently, new molecular therapeutic strategies encompassing gene therapy have been 
developed to selectively target tumour cells and correct, supplement or inhibit cancer 
promoting genes which are defective in normal cellular function. In contrast to the commonly 
utilized pDNA in gene expression studies, the use of mRNA holds promise in efficient gene 
expression and overcoming the cellular barriers limiting the use of pDNA and is therefore 
investigated in this study. The advantages of mRNA based therapy include no requirement 
for nuclear entry, rapid promoter-independent protein expression directly in the cytoplasm, 
no genomic integration and it is suitable for hard-to-transfect cells (Matsui et al., 2015). Non-
viral gene delivery vectors have recently gained much attention due to their superiority over 
viral vectors in terms of simplicity, safety and large loading capacity (Shan et al., 2012). 
However, the development of highly efficient non-viral vectors remains a challenge for 
delivery due to cellular trafficking barriers such cellular uptake, protection, release and 
passage across the nuclear membrane of the genetic cargo (Manjila et al., 2013). 
The application of gold nanoparticles (AuNPs) in nanomedicine and diagnostics is a rapidly 
emerging field due to their facile synthesis, manipulation of parameters such as size, shape, 
stability and dispersity, biocompatibility and unique optical properties such as surface 
plasmon resonance.  
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The high surface-volume-ratio of AuNPs allows for easy functionalisation with biomolecules 
to anchor therapeutic modalities and control reactivity, stability, charge, cellular uptake, 
tissue biocompatibility and toxicity (Sivaramakrishnan et al., 2014). In addition, their inert 
nature, low-toxicity, favourable interaction with cells and ability to stabilize and protect 
nucleic acids has encouraged the use of AuNPs as gene delivery vectors (De Long et al., 
2010).  Nanoparticles that have been functionalised with cationic polymers greatly favour 
solubility, biodegradability, bioavailability and circulation half-life (Pedrosa et al., 2015). In 
addition, cationic polymers aid in effective condensation of nucleic acids via electrostatic 
interactions without compromising functionality, cellular internalisation via endocytosis, 
protection against nuclease degradation and release via the “proton sponge effect” 
(Nayerossadat et al. , 2012). 
Poly-l-lysine (PLL) has been one of the first cationic polymer vectors used in gene therapy 
(Jin et al., 2014). Poly-l-lysine is derived from polymerisation of the N-carboxy-anhydride 
component of lysine and is therefore biodegradable, a characteristic suitable for gene delivery 
(Gascón et al., 2013). In addition, PLL has been reported to cause stress-induced apoptosis 
and hence applied as an anti-tumour agent (Symonds et al., 2005). These characteristics are 
hence exploited when conjugated to AuNP carriers. PLL forms electrostatic interactions and 
hydrogen bonds with citrate stabilized AuNPs resulting in a condensed structure which is 
efficient for binding and protecting nucleic acids. Furthermore, PLL-AuNPs have been used 
in a variety of applications such as biorecognition systems developed for DNA and antibody-
antigen interactions, bactericidal and viricidal vaccines, as scaffolds in tissue repair and as 
stem cell carriers (Stobiecka and Hepel, 2011). However, reports on their use as gene 
delivery vectors are limited with those only stating the efficient electrostatic binding of 
nucleic acid fragments, penetration of eukaryotic membranes and low cytotoxicity. In this 
study, we synthesized and characterized PLL functionalised AuNPs using various chemical 
and physical techniques, assessed their ability to bind and protect luciferase-encoded mRNA 
(Fluc-mRNA), evaluated their cytotoxicity and apoptosis induction and finally their 
transfection efficiency in the HEK293, Caco-2 and MCF-7 cell lines with the aim of 





4.2  Materials and methods 
Ultrapure (18 M ohm) deionized water (Milli-Q Academic, Millipore, France) was utilized 
throughout and all reagents and chemicals were of analytical grade.  
 
4.2.1 Materials 
Gold (III) chloride trihydrate (Mw: 393.83 g/mol, HAuCl4.3H2O), poly-l-lysine 
hydrobromide (Mw: 1000-5000, PLL), 2, 2-dihydroxyindane-1, 3-dione (Ninhydrin, Mw: 
178.14 g/mol, C9H6O4) were supplied by Sigma-Aldrich Chemical Co., (St. Louis, USA). 
Sodium citrate tribasic dehydrate (Mw: 294.20 g/mol, Na3C6H5O7.2H2O), 2-[4-(2-
hydroxyethyl) piperazin-1-yl] ethanesulphonic acid (HEPES, C8H18N2O4S), tris 
(hydroxymethyl) aminomethane [Tris base, Mw: 121.14 g/mol, H2NC(CH2OH)3], sodium 
dihydrogen orthophosphate dehydrate (Mw: 156.01 g/mol, NaH2PO4.2H2O), ethylene diamine 
tetra acetic acid disodium salt (Mw: 372.24 g/mol, EDTA, C10H14N2Na2O8.2H2O), Dodecyl 
sulphate sodium salt (SDS, Mw: 288.37 g/mol, C12H2OSO2Na ), bromophenol blue (Mw: 
669.96 g/mol, C19H10Br4O5S) were supplied by Merck (Darmstadt, Germany). UltraPure
TM 
agarose, RNase free water (1 U/µl, supplied with MnCl2) and UltraPure
TM DEPC-treated 
water were supplied by Thermo Fischer Scientific Inc., (Waltham, Massachusetts, USA).  
Molecular grade ethidium bromide solution (10 mg/ml) was supplied by Promega (Madison, 
Wisconsin, USA).  Fetal Bovine Serum (FBS) was supplied by Hyclone
 GE Healthcare (Utah, 
USA). SYBR Green II RNA gel stain (10 000× concentrate in DMSO) was supplied by 
Cambrex Bio Science Rockland Inc., (Rockland, ME, USA). The Fluc-mRNA was provided 
by the Laboratory of Molecular and Cellular Therapy, Department of Immunology-
Physiology, Vrije University, Brussels, Belgium.  
 
4.3. Synthesis, Characterisation and Nanocomplex Evaluation 
 
4.3.1 Synthesis of citrate reduced colloidal AuNP solution 
The citrate reduction of Gold (III) chloride trihydrate (HAuCl4), adapted from the method of 
Turkevich et al., 1951, was used to synthesize a 0.45 x 10-3 M colloidal AuNP solution. 
Approximately 25 ml of 18 M ohm water was heated to 90C with moderate stirring using a 
MH-4 Analog heating magnetic stirrer (Fried Electric, Israel). Thereafter, 375 µl of a HAuCl4 
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solution (3 x 10-2 M) was rapidly introduced into the vortex of the solution, followed by the 
immediate addition of 1 ml of a 1% (w/v) sodium citrate solution. Subsequently, the solution 
was boiled for 15 minutes until the formation of a ruby red solution containing the desired 
AuNPs was formed. Boiling time was extended for 5 minutes and the resultant AuNP 
solution was cooled and stored at room temperature.  
 
4.3.2 Functionalisation of AuNPs with poly-l-lysine (PLL) 
Functionalisation was carried out by the drop-wise addition of 1 ml of the AuNP solution to 1 
ml of a PLL (1 mg/ml in 18 M ohm water) solution with moderate stirring, producing PLL 
functionalized gold nanoparticles (PLL-AuNPs) in a AuNP:PLL ratio of  1:1. The final 
concentration of PLL in solution was calculated to be 0.5 µg/µl which was diluted to 0.025 
µg/µl for experimental use. Dialysis of the PLL-AuNP solutions against 18M Ohm water at 
room temperature for 2 hours (MWCO: 12-14000 Daltons, Sigma-Aldrich, USA) was 
conducted to remove unbound PLL from the solution and to determine the binding efficiency 
of the AuNPs to PLL. 
 
4.3.3 Inductively Coupled Plasma (ICP) analysis 
Inductively coupled plasma-optical emission spectroscopy (ICP-OES) was used for the 
elemental detection and quantification of the Au concentration in the AuNP solution. 
Analysis was performed on a Perkin Elmer Optima 5300 DV Optical Emission Spectrometer. 
For the analysis, a standard calibration curve was set up with a range of 1-20 ppm using a 100 
ppm Au standard stock solution purchased from Fluka. 
 
4.3.4 Fourier Transformed Infrared Spectroscopy (FTIR) analysis 
FTIR analysis of the AuNPs was conducted in a Spectrum Perkin Elmer spectrophotometer, 
precisely equipped with a Universal ATR sampling accessory using a diamond crystal. 
Spectrum Analysis Software was used to obtain the respective IR spectra. 
 
4.3.5 Qualitative ninhydrin test for amino groups 
The ninhydrin reaction was used as a simple qualitative test to confirm the successful 
functionalisation and the presence of PLL via its amine groups in the PLL-AuNP solution. 
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Briefly, a mixture of PLL-AuNP stock solution and 0.1% ninhydrin solution (1 ml each) was 
boiled for 3-5 minutes with a colour transition from clear to blue/purple colour, indicating a 
positive reaction for the presence of the amine functionalities.  
 
4.3.6 Formation of mRNA:PLL-AuNP complexes  
The nanocomplexes were prepared with various PLL-AuNP/PLL:Fluc-mRNA (w/w) mass 
ratios by adding Fluc-mRNA (0.25 µg/µl in RNase-free water) to increasing amounts of the 
PLL-AuNPs and free PLL for comparative purposes. The nanocomplexes were made up to a 
constant volume of 10 µl with HEPES buffered saline [HBS, (20 mM HEPES; 150 mM 
NaCl), pH 7.4] and incubated at room temperature for 30 minutes to facilitate the formation 
of PLL-AuNP/PLL:Fluc-mRNA nanocomplexes.  
 
4.3.7 UV-Visible spectrophotometry analysis  
Nanoparticle formation was characterized by their optical properties using UV 
spectrophotometry. The absorbance (Abs) readings of the AuNPs, PLL-AuNPs and PLL-
AuNP:Fluc-mRNA [Ratio 0.7:1; Table 4.1] solutions were scanned over a wavelength range 
of 200 nm - 800 nm using a Biomate 3 spectrophotometer (Thermo Fischer Scientific Inc., 
Waltham, Massachusetts, USA) with 18 M ohm water as the blank. The spectrum generated 
for each solution was compared to previous literature to confirm the expected SPR absorption 
of AuNPs in the range of 510 nm - 550 nm (Verma et al., 2014). The dialysed PLL-AuNP 
solution was also measured by UV spectrophotometry to provide an indication of their 
binding efficiency using the following formula:  
unbound PLL (%) = (Abs before dialysis – Abs after dialysis/ Abs before dialysis) x 100%: 
Total bound PLL (%) = 100% - unbound PLL % 
 
4.3.8 Transmission electron microscopy (TEM) 
The ultrastructural morphology, shape, distribution and uniformity of all nanoparticle and 
nanocomplex solutions were assessed using transmission electron microscopy (TEM). 
Briefly, 1 µl of the AuNP, PLL-AuNP and PLL-AuNP:Fluc-mRNA (0.7:1 w/w) solutions 
were spotted onto separate carbon coated Formvar grids and air-dried. Samples were viewed 
using a JEOL-JEM TEM1010 (Jeol, Tokyo, Japan) without warming above -150ºC at an 
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acceleration voltage of 100 kV. The iTEM Soft Imaging Systems (SIS) Megaview III fitted 
with a side-mounted 3-megapixel digital camera was used to capture images of each sample. 
 
4.3.9 Nanoparticle Tracking Analysis (NTA) 
The average individual size and concentration of the nanoparticles and nanocomplexes was 
determined using Nanoparticle Tracking Analysis (NTA), a laser based system providing a 
particle-particle analysis. NTA also determines zeta potential which was used to assess 
colloidal stability of the nanoparticles and nanocomplexes. 
NTA and zeta potential analysis were investigated at 25C using a Nanosight NS500 
Nanoparticle characterization system equipped with NTA version 3.2 Software (Malvern 
Instruments Ltd., Worcestershire, UK). The AuNP, PLL-AuNP (1/500 dilution) and PLL-
AuNP:Fluc-mRNA (1/100 dilution) solutions were prepared and examined in compliance 
with NTA system requirements.  
 
4.3.10 Gel retardation assay 
The minimum concentration and optimal ratio of PLL-AuNPs and PLL required to 
completely bind and complex Fluc-mRNA (0.25 µg/µl) and was determined using the gel 
retardation assay or band shift assay. An agarose gel (2% w/v) fitted with an 8 well comb and 
containing 3 µl of ethidium bromide (10 mg/ml) was prepared. The nanocomplexes for both 
PLL-AuNP and PLL were prepared as in Table 4.1. Naked Fluc-mRNA (0.25 µg/µl) was 
used as a control. Following the 30-minute incubation period for complex formation, 3 µl of 
gel loading buffer [0.25% (w/v) bromophenol blue dye and 40% sucrose] was added to all 
samples and 10 µl of each sample was loaded into separate wells on the agarose gel. 
Electrophoresis was carried out at 50 volts (V) for 30 minutes in a Mini-Sub® electrophoresis 
tank (Bio-Rad Laboratories, Richmond, USA) containing 1x TPE electrophoresis buffer (0.36 
M Tris-HCl; 0.3 M NaH2PO4; 0.1 M EDTA, pH 7.5).  
Thereafter, the gels were viewed under UV transillumination in a Vacutec Syngene G:Box 
gel documentation system and images captured at an exposure time of 1-2 seconds using the 
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4.3.11 Dye displacement/Intercalation assays 
Fluorescence based assays entailing dye displacement were also used to verify complex 
formation and the degree of Fluc-mRNA condensation by PLL-AuNPs and PLL. 
 
4.3.11.1    Ethidium bromide dye displacement 
Fluorescence quenching due to displacement of ethidium bromide (EtBr) was measured at an 
excitation wavelength of 520 nm and emission wavelength of 600 nm using the Glomax® 
Multi-detection system (Promega Systems, Sunnyvale, USA). Approximately 100 µl of HBS 
and 2 µl of EtBr (100 µg/ml) were added to two separate wells on a 96 well FluorTrac flat-
bottom black microplate and mixed thoroughly. Fluorescence was measured and taken as the 
0% baseline relative fluorescence. The fluorescence measurement after addition of 1 µl of 
Fluc-mRNA (0.25 µg/µl) to each well was taken as 100% relative fluorescence. Thereafter, 1 
µl aliquots of the PLL-AuNP solution (0.025 µg/µl) and the PLL solution (0.025 µg/µl) were 
added and fluorescence measurements recorded after each addition until a point of inflection 
in fluorescence was attained. Fluorescence measurements were calculated as relative 
fluorescence (Fr) using the equation:  Fr (%) = (Fi – F0)/ (Fmax - F0) x 100%, where F0 is the 
fluorescence intensity of EtBr/HBS mixtures, Fi is the fluorescence intensity at each 
concentration of PLL-AuNP or PLL and Fmax is the fluorescence intensity of the EtBr/Fluc-
mRNA mixture. The relative fluorescence was then plotted against the mass (µg) of PLL-





4.3.11.2  SYBR Green dye displacement 
The SYBR Green RNA II gel stain (10 000× concentrated in DMSO) was additionally 
utilised for displacement studies since this dye is more sensitive and selective for RNA 
molecules than EtBr. This assay was performed as described in 4.3.11.1 above by using the 
SYBR Green dye and measuring fluorescence at an excitation and emission wavelength of 
497 nm and 520 nm, respectively.  
 
4.3.12  Nuclease Protection assay 
The extent of protection offered by the PLL-AuNP and PLL to the Fluc-mRNA in an 
environment that imitates that of an in vivo system was assessed using the nuclease protection 
assay. Based on the results obtained from the gel retardation assay, sub-optimum, optimum 
and supra-optimum ratios for PLL-AuNP:Fluc-mRNA and PLL:Fluc-mRNA complexes were 
selected and prepared as outlined below (Table 4.2). The final volume of the complexes was 
made up to 10 µl with HBS and the mixtures incubated at room temperature for 30 minutes to 
allow for complex formation. Thereafter, FBS was added to each complex to a final 
concentration of 10%. Naked Fluc-mRNA (0.25 µg/µl) was used as a positive control and 
naked Fluc-mRNA (0.25 µg/µl) containing FBS was used as a negative control. To facilitate 
nuclease digestion, all samples containing FBS were incubated at 37C for 4 hours. The 
reaction was terminated by the addition of EDTA to a final concentration of 10 mM EDTA. 
Subsequently, 5% SDS was added to all samples to a final concentration of 0.5% and the 
samples incubated at 55C for 20 minutes. The samples were then subjected to agarose gel 
electrophoresis for 30 minutes as previously described (4.3.10). 
 


































































0 0 0.15 0.175 0.2 0.125 0.15 0.175 
mRNA (µg/µl) 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
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4.4 In Vitro cell culture studies 
 
4.4.1 Cell culture materials and reagents 
Phosphate-buffered saline tablets [PBS, (140mM NaCl, 10mM phosphate buffer, 3mM 
KCl)], 3-[(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] (MTT, Mw: 414.3 
g/mol, C1H1BrNS) and Dimethyl Sulfoxide [DMSO, Mw: 78.13 g/mol, (CH3)2SO] were 
supplied by Merck (Darmstadt, Germany). Research Grade Fetal Bovine Serum was supplied 
by Hyclone GE Healthcare (Utah, USA). Sterile filtered Eagle’s Minimum Essential Medium 
(EMEM) with L-glutamine (4.5 g/ml), Penicillin/ Streptomycin/ Amphotericin B (100×) 
antibiotic mixture [Amphotericin B (25 mcg/ml), NaCl (8.5 mg/l) Potassium penicillin 
(10 000 units/ml), Streptomycin sulphate (10 000 mcg/ml)] and Trypsin-versene-EDTA 
mixture [versene-EDTA (200 mg/l), Trypsin (170 000 U/l)] were supplied by Lonza Bio 
Whittaker (Verviers, Belgium). The luciferase assay kit consisting of the luciferase cell 
culture lysis reagent (5×) [25 mM Tris-phosphate, (pH 7.8), 2 mM dithriothreitol, 2 mM 1,2-
diaminocyclohexane-N,N,N’,N’-tetra-acetic acid, 10% (v/v) glycerol, 1% (v/v) triton X-100], 
luciferase assay reagent (20 mM tricine, 1.1 mM Magnesium carbonate hydroxide, 
pentahydrate, 2.7 mM Magnesium sulphate, 0.1 mM EDTA, 33.3 mM dithriothreitol, 270 
µM coenzyme), Molecular grade ethidium bromide solution (10 mg/ml) [3,8-Diamino-5-
ethyl-6-phenylphenanthrinidium bromide and EtBr, (Mw: 394.31 g/mol, C21H20BrN3) were 
purchased from Promega (Madison, Wisconsin, USA). Acridine Orange hemi (zinc chloride) 
salt [3,6-Bis(dimethylamino)acridine hydrochloride zinc chloride double salt], bicinchoninic 
acid solution [1% 2,2’-Biquinoline-4,4-dicarboxylic acid disodium salt, 0.16% Sodium 
tartrate, 0.4% Sodium hydroxide, 2% Na2CO3.H2O, 0.95% NaHCO3, (pH 11.25)], Copper 
(II) sulfate solution [4% (w/v) prepared from copper (II) sulfate pentahydrate] and protein 
standard (1ml/amp, 1mg BSA/ml in 0.15 M NaCl, 0.05% NaN3) were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, USA). All sterile tissue culture plasticware were supplied 
by Corning Inc., (New York, USA). Human embryonic kidney cells (HEK293) was provided 
by the Anti-Viral Gene Therapy Unit, Medical School, University of Witwatersrand, human 
epithelial colorectal adenocarcinoma cells (Caco2) was purchased from Highveld Biologicals 
(Pty) Ltd, Kelvin, RSA and the MCF-7 (HTB-22™) breast cancer line was purchased from 






4.4.2 Cell culture maintenance 
All techniques were aseptically performed with cell culture work conducted in an Airvolution 
Class II Biohazard cabinet. Cryogenically frozen cells were thawed in a 37°C water bath and 
cells then pelleted at 3000 rpm for 1 minute in an Eppendorf centrifuge (Model 5415D, New 
York, USA). The pelleted cells were suspended in 1 ml of fresh complete medium [EMEM, 
10% (v/v) FBS and 1% (v/v) antibiotic mixture] and transferred to a cell culture flask 
containing 5 ml of complete medium. The cells were then incubated at 37°C in a Steri-cult 
HEPA class 100 CO2 incubator (Thermo-Electron Co., Waltham, Massachusetts, USA) and 
growth was routinely monitored under a Nikon TMS inverted light microscope (Nikon Co., 
Tokyo, Japan). Medium was changed when necessary and cells sub-cultivated as desired 
upon confluency. 
For sub-cultivation or trypsinisation, the spent medium was removed and cells were washed 
with 5 ml PBS, followed by the addition of 1 ml trypsin-versene. To monitor the action of 
trypsin and the effect of “rounding off”, the cells were viewed under the inverted microscope. 
The trypsinization reaction was terminated by the addition of 2 ml complete medium to the 
cells which were then dislodged from the flask surface by gently tapping the flask against the 
palm of the hand. Prior to cell culture experiments, a cell count was conducted under the 
inverted microscope using a haemocytometer slide (Marienfield-Superior, Germany). The 
cells were then sub-divided into cell-culture flasks for routine maintenance and seeded into 
multi-well plates for the various cell culture assays or cryopreserved for future studies. 
For cryopreservation, trypsinized cells were pelleted at 3000 rpm for 5 minutes and then 
suspended in 0.9 ml complete medium and 0.1 ml of DMSO cryoprotective storage medium.  
This suspension was then mixed and dispensed into individual cryogenic vials which were 
placed into a Nalgene™ “Mr Frosty” Cryo 1°C freezing container (Thermo Fischer Scientific 
Inc., Waltham, Massachusetts, USA), filled with isopropanol. Freezing was achieved at a rate 
of -1°C per minute to a temperature of -70°C in a biofreezer (Nuaire, Lasec laboratory and 
Scientific Equipment). Thereafter, the cryogenic vials were transferred to a cryobox and 
stored in a biofreezer at -80°C for short term storage or in liquid nitrogen for long term 





4.4.3 MTT cytotoxicity assay 
HEK293, Caco-2 and MCF-7 cells were separately trypsinized and seeded into clear 48-well 
plates at a density of 7.8 x 104, 9.6 x 104 cells/well and 2.1 x 105 cells/well, respectively. 
Cells were incubated at 37°C for 24 hours to facilitate attachment and growth. Thereafter, the 
medium was replenished with fresh complete medium and the prepared complexes (in 
triplicate) (Table 4.2) were added to the respective wells. A positive control (100% viability) 
containing cells only was set up. The cells were then incubated at 37°C for 48 hours after 
which the spent medium was replenished with 200 µl of fresh complete medium and 200 µl 
of MTT reagent (5 mg/ml in PBS) and the cells incubated at 37°C for 4 hours. Thereafter, the 
MTT containing medium was discarded and the resultant formazan crystals were solubilized 
with gentle shaking in DMSO (200 µl). Absorbance at 570 nm was then measured in a 
Mindray MR-96A microplate reader (Vacutec, Hamburg, Germany) against a DMSO blank. 
Results were calculated as cell viability (%) using the following equation: 
Abs (Test)/ Abs (control) x 100 %. 
 
4.4.4 Luciferase reporter gene assay 
 
The luciferase reporter gene assay was conducted to determine the transfection efficiency of 
the complexes and is based on the measurement of bioluminescence as a direct correlation of 
luciferase activity. Cells were seeded and complexes prepared in triplicate and added as in 
4.4.3.  Two controls, one containing cells only and one containing naked Fluc-mRNA (0.25 
µg/µl) were included.  
The cells were then incubated at 37°C for 48 hours, followed by removal of the spent 
medium and rinsing of the cells with 200 µl of PBS. Thereafter, 80 µl of 1x luciferase cell 
culture lysis reagent was added to the cells which were then shaken for 15 minutes at 30 
rev/min on a STR6 platform shaker (Stuart Scientifc, Staffordshire, UK). The lysed cells 
were then harvested and the cell lysates pelleted at 12000 x g using an Eppendorf centrifuge.  
Approximately 20 µl of each cell free supernatant was transferred to individual wells on a 96-
well FluorTrac flat-bottom white microplate to which 50 µl of the luciferase assay reagent 
was added. The samples were immediately mixed and luminescence read using a GloMax 
Multi-detection system (Promega Biosystems, Sunnyvale, USA), operated by Instinct 
software, primed with luciferase assay reagent and the Photo Multiplier Tube (PMT) 
activated prior to measurements. 
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The protein content of each cell free extract was determined using the bicinchoninic acid 
(BCA) assay and absorbance was measured at 562 nm in a microplate reader. All 
luminescence readings were normalized against the protein content and expressed as relative 
light units per milligram protein (RLU/mg protein).  
 
4.4.5 Acridine Orange/Ethidium Bromide (AO/EB) apoptosis assay 
Cells were seeded, incubated and complexes added as in 4.4.3. However, complex 
preparation was based on the optimal ratios obtained from the MTT cytotoxicity and 
luciferase reporter gene assays as outlined in Table 4.3 below. The positive control used was 
cells not exposed to the complexes. After a 24-hour incubation at 37C, the spent medium 
was removed, cells washed with 200 μl of PBS and stained with 10 μl of the AO/EB dye (0.1 
μg/µl acridine orange and 0.1 μg/µl EtBR in PBS) at room temperature for 5 minutes. The 
stain was then removed and the cells washed with 200 μl of PBS. Apoptotic-induced 
morphological changes of the treated cells were compared against the control using an 
Olympus inverted fluorescence microscope (200× magnification) fitted with a CC12 
fluorescent camera, an excitation filter of 450-490 nm, a barrier filter of 520 nm and Soft 
Imaging System (SIS) software (Olympus Co., Tokyo, Japan). The apoptotic index for each 
sample was calculated using the following equation:  
Apoptotic index = number of apoptotic cells / total number of cells 
 
Apoptosis was detected based on the selectivity of the two dyes, acridine orange which 
penetrates both the living and dead cells producing green fluorescence, whereas EtBr 
produces red fluorescence when cells have altered membranes. After visual analyses, the cells 
were harvested into 200 µl of PBS and transferred to individual wells on a FluorTrac flat-
bottom black microplate. Fluorescence was measured at an excitation wavelength of 520 nm 
and emission wavelength of 600 nm in the Glomax® Multi-detection system. The 
fluorescence readings were averaged over three replicates (n=3) and reported as fluorescent 






Table 4.3. Composition of complexes used in the AO/EB apoptosis assay. 
Composition of samples PLL-AuNP PLL 
 





PLL-AuNP/PLL (µg) 0.2 0.175 
 
Fluc-mRNA (µg/µl) 0.25 0.25 
 
 
4.4.6 Statistical analysis 
All data obtained was calculated as the mean ± standard deviation (±SD n=3) and plotted on 
graphs using Microsoft Excel 2010 (Microsoft, USA). Using the Graphpad Instat Prism 4.0.3 
software, the one-way analysis of variance (ANOVA) test was conducted for multi-group 
comparisons of the calculated means. Thereafter, the Dunnett’s post hoc test was carried out 
for the MTT cytotoxicity assay results and the Tukey-Kramer post hoc test was carried out 
for the luciferase reporter gene assay results. Statistical significance (P) values determined to 
be less than 0.05 were regarded as significant and represented on the graph as *** p < 0.001, 
** p < 0.01 and * p < 0.05.  
 
4.5  Results and Discussion 
 
4.5.1 Characterization of nanoparticles and complexes 
 
4.5.1.1  Chemical analysis 
 
ICP analysis has been proven as an efficient technique for elemental determination (Szpunar, 
2005). The concentration of the synthesized AuNP was confirmed by ICP against a standard 
Au sample by correlation of the electron signals emitted at each wavelength (Appendix A1).  
FTIR spectroscopy is a useful tool for identifying chemical bonds of inorganic and organic 
molecules generating an infrared absorption spectrum which serves as a “molecular 
fingerprint” that is characteristic to a certain molecule. FTIR spectroscopy confirmed the 
composition of the AuNP, PLL and PLL-AuNP solutions (Appendix A2). Citrate-capped 
AuNPs exhibited characteristic absorption peaks at 1635.63 cm−1, indicating the stretching of 
101 
 
the C=O bond of the carboxylic carbonyl group and 3272.20 cm−1 indicating the stretching of 
O-H bonds as compared to previous literature (Chen et al., 2013). The spectrum of PLL 
exhibited characteristic absorption peaks at 1637.91 cm–1 for the amide I band which 
indicates the C=O stretch vibration band, 2020.63 cm−1 indicating the C-N stretch, 2184.69 
cm−1 indicating the C-H stretch and 3269.95 cm−1 for the amide A band indicating the N-H 
stretch vibration as compared to previous literature (Bathrinarayanan et al., 2013; Rozenberg 
and Shoham, 2007; Zhuang et al., 2015). These absorption peaks are characteristic for the 
random coil formation at pH 7 which was utilized in this assay.  
In contrast to the AuNP FTIR spectrum, the PLL-AuNP spectrum exhibits two additional 
absorption peaks at 2020.63 cm−1 and 2184.69 cm−1, indicating the C-N and C-H stretch of 
PLL, respectively. In addition, the characteristic peaks of the C=O and O-H stretches of the 
AuNPs increased to 1636.56 cm−1 and decreased to 3270.93 cm−1 after functionalisation with 
PLL. These results indicate that the reducing ends of the citrate ions formed interactions with 
the amino groups of PLL, as reported in previous literature (Shen et al., 2012).  
 
4.5.1.2 UV-Vis optical spectrophotometry analysis  
AuNPs exhibit surface plasmon resonance (SPR) which occurs when the electron cloud 
oscillates on the AuNP surface, resulting in electromagnetic radiation absorption at a 
particular energy (Philip, 2008) and enhances the absorption and scattering properties of 
AuNPs (Radwan and Azzazy, 2009). The ruby red colour of a AuNP solution arises from 
their strong SPR absorption in the visible region at 520 nm (Jain et al.  2006), as confirmed in 
this study (Figure 4.1). UV-vis spectroscopy provides valuable information such as 
approximation of size, concentration and aggregation level of AuNPs (Amendola and 
Meneghetti, 2009). Functionalisation with PLL (Figure 4.1) resulted in a red-shift of SPR 
absorbance to 600 nm which was also visually confirmed by the colour transition in solution 
from ruby red to black upon functionalisation of the AuNPs with PLL. Factors such as size, 
shape, surface composition and charge, solvent, temperature and aggregation of AuNPs have 
been reported to induce a red-shift coupled with broadening of the absorbance peak and 
decrease in intensity as seen in Figure 4.1 (Yeh et al., 2012). This occurrence of a red-shift 
has previously been reported for the functionalisation of AuNPs with PLL (Stobiecka and 
Hepel, 2011). A red-shift was also observed upon complex formation of PLL-AuNP with 
Fluc-mRNA and with a SPR absorbance at 620 nm (Figure 4.2). The absorbance of the PLL-
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AuNP recorded after dialysis further indicated the successful removal of unbound PLL by 
dialysis. The percentage of bound PLL was determined to be 31%.   
 
 
Figure 4.1: UV-Vis spectrum of AuNPs, PLL-AuNPs before and after dialysis indicating the shift in 












4.5.1.3 Qualitative ninhydrin test for amine groups 
The ninhydrin test was used as a simple qualitative test to confirm the presence of –NH2 
groups and hence the functionalisation of AuNPs with PLL. The ninhydrin reagent reacts 
with a variety of primary and secondary amines present in the structure of PLL. Heating 
results in the hydrolysis of the amines to produce a blue-purple colour complex commonly 
known as Ruhemann’s purple (Wu et al., 2005) as evidenced in this study (Figure 4.3).  
 
Figure 4.3: The positive dark purple PLL-AuNP reaction produced in the ninhydrin test. 
 
4.5.1.4 Transmission electron microscopy (TEM) 
TEM involves the use of passing a beam of electrons through a nanoparticle sample to 
produce a high-resolution image providing information such as size, shape, self-organisation 
and core to core spacing of the AuNPs in solution (Zhou et al., 2009). Both AuNPs  and PLL-
AuNPs (Figure 4.4 A-B) displayed as homogenous, spherical and smooth particles with 
monodisperse distribution with AuNPs appearing more dense, similar to previously reported 
studies (Stobiecka and  Hepel, 2011; Verma et al., 2014).  
The excellent dispersion of the AuNPs are a result of electrostatic stabilization induced by the 
sodium citrate capping, causing the AuNP atoms to repel each other (Polte, 2015). PLL 
functionalisation (Figure 4.4 B) resulted in agglomerate and chain-like structures due to 
electrostatic interactions between the citrate-capped AuNPs and PLL. The PLL-AuNP:Fluc-
mRNA nanocomplexes (Figure 4.4 C) are assumed “flower-like” branched structures due to 
the condensation of Fluc-mRNA. This occurrence of “flower-like” structures has previously 
been reported for AuNP–protein conjugation (Das et al., 2012).  
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Figure 4.4: Transmission electron micrographs of (A) AuNPs, (B) PLL-AuNPs at 50 000 ×, and (C) 
PLL-AuNP:Fluc-mRNA at a magnification of 500 000 ×. Bar = 50 nm. 
 
4.5.1.5 Nanoparticle tracking analysis (NTA) 
The size of nanoparticles plays a vital role in cellular interaction. Nanoparticles up to 200 nm 
are suitable for cellular uptake by receptor-mediated endocytosis. The use of NTA served to 
determine the size, zeta potential, colloidal stability and distribution of the synthesized 
AuNPs. NTA is a pioneering technology based on a particle-by-particle methodology for 
determining the average size, size distribution and concentration of nanoparticles in a 
population (Carr and Wright, 2008).  
The NTA software identifies and tracks individual nanoparticles moving under Brownian 
motion, allowing for the diffusion coefficient to be calculated. Particle size is related to the 
movement of the nanoparticle and calculated according to the Stokes-Einstein equation 
(Filipe et al., 2010).  
Table 4.4 and Appendix B show the average sizes, zeta potentials and concentrations for the 
AuNP, PLL-AuNP and the nanocomplex. The average size of the AuNPs was 65.9 +/- 9.8 nm 
which increases to 90.4 +/- 15.0 nm for the PLL-AuNP, possibly due to the functionalization 
and the formation of agglomerates and chain-like structures as seen under TEM. Upon Fluc-
mRNA binding, the size of PLL-AuNP:Fluc-mRNA nanocomplex decreased to 89.4 nm due 
to condensation of the mRNA, correlating to the “flower-like” condensed structures seen 
under TEM. All formulations displayed sizes below 100 nm, making them suitable for gene 
delivery purposes. 
Apart from size, the surface charge of nanocomplexes influence their colloidal stability, 
intracellular uptake, cytotoxicity and release of the therapeutic cargo (Pedrosa et al., 2015). 
(B)   (A) (C) 
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Furthermore, the colloidal stability of AuNPs is an important parameter in preventing 
aggregation when introduced into an in vivo system. 
  
Table 4.4. Size, zeta potential and concentration of the nanoparticle solutions obtained from 
nanoparticle tracking and zeta potential analysis. 






AuNP 65.9 +/- 9.8  -7.3 +/- 1.6  2.55e+008 +/- 1.69e+006  
PLL-AuNP 90.4 +/- 15.0  -5.3 +/- 0.2  2.94e+008 +/- 5.93e+006  
PLL-AuNP:Fluc-mRNA 89.4 +/- 0.0  -97.1 +/- 102.4  7.25e+007 +/- 6.86e+007  
 
Zeta potential is the sum of potential differences between the surface and the slipping plane 
of the stationary fluid layer of a nanoparticle (Arjmandi et al., 2012). Zeta potential 
measurements detect the magnitude of repulsion between particles and their tendency to 
aggregate which can be used to confirm stabilization by functional ligands (De Long et al., 
2010).   
In general, an excellent zeta potential (greater than 25 mV or -25 mV) indicates the formation 
of stable nanoparticles and as the zeta potential approaches the point of zero the attraction 
between nanoparticles surpasses the repulsive forces between the nanoparticles causing 
aggregation (Ivanov, 2011). Thus, zeta potential analysis is important for determining 
nanoparticle surface chemistry and long-term stability.  
From the zeta potential analysis (Table 4.4), it was observed that the AuNPs (-7.3 +/- 1.6 
mV) and PLL-AuNPs (-5.3 +/- 0.2 mV) did not have excellent colloidal stability. This can be 
correlated to the formation of agglomerates and chain-like structures as seen under TEM. 
PLL is a positively-charged polymer and therefore should confer a positive charge to the 
AuNPs upon functionalisation. The PLL-AuNP:Fluc-mRNA nanocomplexes produced a zeta 
() potential increase to -97.1 +/- 102.4 mV, indicative of excellent colloidal stability which 
could be attributed to the high condensation of the mRNA. Overall, the functionalized AuNPs 






4.5.2 Assessment of PLL and PLL-AuNP binding to Fluc-mRNA 
 
4.5.2.5 Gel retardation assay  
The gel retardation or band shift assay was conducted to determine the ability of PLL-AuNPs 
and PLL to bind and complex the mRNA. This assay determined the point of saturation 
beyond which further loading of the PLL-AuNPs or PLL caused no further migration of the 
mRNA into the gel due to complete binding of mRNA by the nanoparticle, causing it to 
remain in the well as an electroneutral complex. Hence, partial binding of the Fluc-mRNA 
will result in free migration of the negatively-charged molecule from the cathode to the 
anode. Figure 4.5 A-B shows the binding of the Fluc-mRNA to varying concentrations of 
PLL-AuNP and PLL, respectively. Fluc-mRNA (0.25 µg/µl) served as a control. The 
endpoint or optimal ratio for each assessment is indicated by a white arrow wherein 
electroneutrality was achieved.  
It was observed that the amount of PLL-AuNP and PLL complexes retained in the wells 
increased with increasing PLL-AuNP and PLL concentrations, respectively. Electroneutrality 
and optimal binding ratios were achieved for PLL-AuNP:Fluc-mRNA (Figure 4.5 A) at a 
ratio of 0.7:1 (w/w) (lane 8) and for PLL:Fluc-mRNA (Figure 4.5 B) at a ratio of 0.6:1 (w/w) 
(lane 7). The differences between the binding ratios can be attributed to the greater 
availability of positive charges of PLL particles to effectively bind the Fluc-mRNA than 
PLL-AuNPs as many of the latter’s positive-charges are involved in other interactions. Both 
PLL-AuNP and PLL have shown to efficiently bind Fluc-mRNA low concentrations. 
                    
Figure 4.5: Gel retardation study of (A) PLL-AuNP:Fluc-mRNA and (B) PLL:Fluc-mRNA 
complexes. Incubation mixtures (10 µl) in 20 mM HEPES, 150 mM NaCl (pH 7.5) contained varying 
amounts of (A) PLL-AuNP and (B) PLL in lanes 1–8 (0, 0.025, 0.05, 0.075, 0.1, 0.125, 0.15, 0.175 
µg) and Fluc-mRNA (0.25 µg). 
  




4.3.2.2 Dye displacement/Intercalation assays 
Fluorescent intercalation displacement assays have been widely used as diagnostic tools to 
confirm the interactions and binding affinities of small ligands to therapeutic molecules (Sau 
et al., 2012). These intercalation assays are based on the displacement of mRNA-intercalated 
dye by PLL-AuNPs and PLL used in this study, resulting in a quenching of fluorescence. As 
the dye is displaced, a point of inflection in fluorescence is reached, correlating to the 
optimum concentration of the PLL-AuNPs or PLL required to fully bind the mRNA. From 
Figures 4.6 and 4.7, it can be observed that both the PLL-AuNP and PLL solutions were able 
to successfully displace the dye from the Fluc-mRNA. As with the gel retardation study, it 
was observed that a lower concentration of PLL was required to fully bind the Fluc-mRNA in 
comparison to PLL-AuNPs.  
In both methods (Figure 4.6 and 4.7), fluorescence decreased in a step-wise manner as a 
result of the mRNA-intercalated dye being displaced upon the binding of the nanoparticles to 
mRNA. In the EtBr assay, the concentration required to fully condense the Fluc-mRNA was 
0.325 µg for PLL-AuNP and 0.275 µg for PLL which were higher than those obtained from 
the gel retardation assay. This observation may be due to the intercalating mechanism of EtBr 
being more specific for interaction with the base pairs of the hydrophobic interior of double-
stranded DNA through Van der Waal’s forces  (Banerjee et al., 2014). In contrast, mRNA 
folds back on itself to produce local base pairing for intercalation with EtBr, hence the 
variation in results. This technique has previously been reported successful for the study of 
AuNP-DNA conjugates (Jang et al., 2009). However, it has not been reported for the 
evaluation of AuNP-mRNA conjugates.  
Hence, the additional use of the SYBR green assay has a higher affinity for RNA and has a 
greater sensitivity limit (Lonza Rockland Inc., 2007). In this assay (Figure 4.7), the 
concentration required to fully bind the Fluc-mRNA was 0.125 µg for PLL-AuNP and 0.175 
µg for PLL. These values correlated with those obtained from the gel retardation assay, thus 





Figure 4.6: Comparison of the relative fluorescence between the PLL-AuNP and PLL complexes 
using the EtBr intercalation assay. Arrows indicate the point of inflection. 
 
 
Figure 4.7: Comparison of the relative fluorescence between PLL-AuNP and PLL complexes using 




4.5.3 Nuclease protection assay 
The presence of serum nucleases in culture in vitro and biological fluids in vivo poses a 
challenge in safe gene delivery applications due to risk of nucleic acid degradation. Hence, 
the choice of the delivery vehicle is crucial. Molecular RNA are reported to have short half-
lives and are less stable than RNA conjugated to AuNPs due to direct degradation by RNases, 
reducing their efficacy (Giljohann et al., 2009).  
The sub-optimum, optimum and supra-optimum binding ratios from the gel retardation 
studies were used. Naked undigested Fluc-mRNA, the positive control (C1, Figure 4.8), 
presented a single distinctive bright band whereas FBS-digested Fluc-mRNA, the negative 
control (C2, Figure 4.8), showed complete digestion. The addition of SDS to the complexes 
after FBS treatment served to facilitate the release of the Fluc-mRNA from the 
nanocomplexes. Digested Fluc-mRNA will appear as a smear on the gel similar to the 
negative control (C2) whereas undigested Fluc-mRNA will appear as a distinct band as 
exhibited by the positive control (C1).  
Lane 1 (Figure 4.8) showed minimal digestion of the mRNA, indicating that the amount of 
PLL-AuNP at the sub-optimum ratio provided some but not total protection of the Fluc-
mRNA. However, at the supra-optimum and optimum ratios (lane 2 and 3) no digestion was 
observed, indicating complete protection of Fluc-mRNA by PLL-AuNP at the weight ratios 
of 1:08 and 1:0.9. PLL also offered complete protection to Fluc-mRNA at all ratios as no 
digestion of Fluc-mRNA was observed (Lanes 4-6, Figure 4.8) which could be due to the 
more compact binding offered by the PLL as a result of its density of amine groups that are 
adumbrated upon functionalization with the AuNPs. 
  
Figure 4.8: Nuclease digestion of PLL-AuNP:Fluc-mRNA and PLL:Fluc-mRNA complexes. 
Incubation mixtures (10 µl) in 20 mM HEPES, 150 mM NaCl (pH 7.5) contained a constant amount 
of Fluc-mRNA (0.25 µg) in all lanes and varying amounts of PLL-AuNP, lanes 1-3 (0.15, 0.175, 0.2 
µg) and PLL, lanes 4-6 (0.125, 0.15, 0.175µg). C1 contained undigested Fluc-mRNA and C2 
contained FBS-digested Fluc-mRNA. 
 C1    C2     1      2     3     4      5      6 
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4.5.4 In Vitro cell culture studies 
 
4.5.4.1  Cell culture maintenance 
All cell lines (Figure 4.9 A-C) were successfully propagated in complete medium (EMEM, 
10% FBS and 1% antibiotic) with HEK293 cells (Figure 4.9 A) showing an epithelial 
fibroblast morphology, Caco-2 cells (Figure 4.9 B) a polarized epithelial morphology and 
MCF-7 cells exhibited a dome-like morphology (Figure 4.9 C). 
      
Figure 4.9: Images of cell lines (A) HEK293, (B) Caco-2 and (C) MCF-7 using phase contrast 
microscopy at a 10 000× magnification. 
 
 
4.5.4.2  MTT cytotoxicity assay 
Understanding the extent and mechanisms of cytotoxicity associated with exposure to 
cationic polymer-based nanoparticles is imperative as their toxicological profiles in vitro can 
be used as an indication for future in vivo applications.  
The MTT is a simple colorimetric assay which is based on the mitochondrial enzymatic 
activity in cells. Metabolically active cells possess mitochondrial succinate dehydrogenases 
that reduce MTT, a yellow-brown solution, to a water-insoluble blue-purple formazan 
product which can be solubilized and absorbance measured as an indicator of the 
cytotoxicity.  
In the HEK293 cell line (Figure 4.10 A), a general trend was seen wherein the cell viability 
decreased as the ratio of PLL and PLL-AuNP to Fluc-mRNA increased. Maximum cell 
viability of 116% and 82% was observed at the sub-optimal ratio (ratio 1) for both PLL and 
PLL-AuNP, respectively. For the Caco-2 cell line (Figure 4.10 B), the cell viability increased 
as the ratio of PLL and PLL-AuNP to Fluc-mRNA increased. Maximum cell viability of 78% 
and 100% was observed at the supra-optimal ratios (ratio 3) for PLL and PLL-AuNP, 
respectively. In the MCF-7 cell line (Figure 4.10 C), the cell viability decreased as the ratio 
(A) (B) (C) 
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of PLL to Fluc-mRNA increased but increased as the PLL-AuNP to Fluc-mRNA ratio 
increased. Maximum cell viability of 62% and 99% was observed at the sub-optimal ratio 
(ratio 1) for PLL and the supra-optimal ratio for PLL-AuNPs (ratio 3), respectively.  
Overall, PLL nanocomplexes were less tolerated by all cell lines compared to the PLL-AuNP 
nanocomplexes. This is more evident in the MCF-7 cells with a maximum cell death of 50% 
being recorded at the supra-optimal ratio.  
 




















































Figure 4.10: MTT cytotoxicity assay of complexes in cell lines: (A) HEK293, (B) Caco-2 and (C) 
MCF-7. Data represented as means ± SD (n=3), * p<0.05, **p<0.01 and **p<0.001 were considered 
statistically significant as determined by the Dunnet test. 
 
PLL exhibited growth stimulation effects at lower ratios in the HEK293 cell line and at 
higher concentrations in the Caco-2 cell line when compared to their respective controls. This 
may attributed to the normal cellular function of PLL in the stimulation of immunoglobulin 
production such as interferon-β. Increased cellular proliferation in astrocytes was also 
observed (Stobiecka and Hepel, 2011). Other studies have reported the excessive cytoplasmic 
accumulation of PLL in cells leading to the disruption of homeostasis mechanisms which 
tightly regulate intracellular polyamine concentration, thus inducing mitochondrial 
permeabilization (Stefanneli et al., 2000) which may have played a role on the cytotoxic 
effects seen in the MCF-7 cell line. The toxicity of AuNPs are influenced by several factors 
such as their synthesis method, size, hydrodynamic diameter, shape, surface composition, 
charge, density, hydrophobicity, dose, administration route and incubation time. It has also 
been reported that larger nanoparticles have a high surface area to volume ratio which 
provides platforms for an increase in surface particle activity (Van Doren et al., 2011). The 
size of the PLL-AuNP:Fluc-mRNA complex was 89.4 nm, indicating their susceptibility to 
various surface particle activities with the cells contributing to the toxic effects seen in the 
HEK293 and Caco-2 cell lines at higher concentrations.  
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In general, the cell viability results show that treatment with these complexes are 
concentration or dose dependent and cell type specific. Overall, both nanocomplexes 
performed similarly in all cell lines with cell viability over 50% at all ratios. 
 
4.5.4.3 Luciferase reporter gene assay 
PLL-AuNPs have been proven as highly efficacious for the delivery of plasmid DNA and 
surpasses most commercial vectors (Ghosh et al., 2008). However, their efficacy for the 
delivery of mRNA has not yet been evaluated. This study hopes to answer some of these 
questions. The luciferase reporter gene assay is based upon the bioluminescent measurement 
of firefly luciferase (Photinus pyralis) activity which catalyses the conversion of the substrate 
luciferin to an enzyme-bound intermediate luciferyl-AMP via an ATP-dependent reaction 
(Fan and Wood, 2007).  
This intermediate then undergoes an oxidative decarboxylation reaction to generate the final 
product oxyluciferin in a high-energy state producing a yellow-green light or 
bioluminescence. Only successfully transfected cells will emit luminescence. The intensity of 
light emission is directly proportional to the level of luciferase activity and is measured as 
relative light units (RLU) at 560 nm. The RLU measurements are normalized against the 
soluble protein content in the cell lysates determined using the BCA assay.  
In all three cell lines, the best transgene activity was observed at the sub-optimal ratios (ratio 
1) for both the PLL and PLL-AuNP:mRNA complexes ( Figures 4.11 A-C). Maximum 
recorded luciferase activity for the PLL and PLL-AuNP:mRNA complexes  were 1.07 x 105 
and 1.5 x 105 RLU/mg protein in the HEK293 cell line (Figure 4.11 A), 4.7 x 105 and 6.4 x 
105 RLU/mg protein in the Caco-2 cell line (Figure 4.11 B) and 5.3 x 103 and 6.9 x 103 
RLU/mg protein in the MCF-7 cell line (Figure 4.11 C). 
In all cell lines, a general trend was seen wherein the luciferase activity decreased as the ratio 
of PLL and PLL-AuNP to Fluc-mRNA increased, indicating that transfection efficiency was 
concentration dependent. This observation may be related to the high compaction and 
restricted release of Fluc-mRNA which is due to the high binding efficiency of PLL and 
PLL-AuNP, as established by the band shift and dye displacement assays. 
Overall, PLL-AuNP:Fluc-mRNA complexes displayed significantly higher trangene activity 
than PLL:Fluc-mRNA complexes, indicating that the transfection efficiency of PLL was 
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improved due to its conjugation with the AuNPs, as previously reported (Joshi et al., 2004). 
The transfection and binding efficiency of PLL to nucleic acids are linearly correlated to the 
length and molecular weight of PLL (Segura and Shea, 2001).  
Functionalised AuNPs have been reported to be taken up voluntarily by cells by passive 
mechanisms with their intracellular uptake and distribution being dependent on 
characteristics such as zeta potential, surface modification, shape and size (Huefner et al., 
2014). For positively charged amine functionalised AuNPs the mechanism of internalization 
involves their interaction with the negatively charged cell membrane (Sandhu et al., 2002). In 
this study, all nanocomplexes were less than 100 nm in size, allowing for easier uptake by the 
cells. Furthermore, the higher transgene expression obtained for the PLL-AuNP:Fluc-mRNA 
compared to the PLL-AuNP complexes could be related to the zeta potential differences with 
the latter having a negative zeta potential and was also less stable. The PLL-AuNP:Fluc-
mRNA nanocomplexes had a high positive zeta potential, allowing for increased interaction 
with the negatively charged cellular membrane and better stability overall.  
It has been proposed that the formation of a protein corona on the AuNP surface may be a 
possible mechanism for the recognition and subsequent internalisation of the AuNPs into the 
cells by receptor-mediated endocytosis (Giljohann et al., 2007). Experimental procedures and 
parameters such as concentration and exposure time also influence their cellular uptake and 
distribution (Mironava et al., 2010).  
From the results, it can be concluded that transfection activity, similar to the cytotoxicity, was 
cell specific with Caco-2 cells producing the highest gene expression for both 
nanocomplexes. Interestingly, Caco-2 cells also best tolerated these nanocomplexes which 
correlated into a better transfection efficiency. The synthesized PLL-AuNPs properties such 
as excellent colloidal stability, ability to protect the Fluc-mRNA and inherent low 











Figure 4.11: Luciferase gene expression activity of nanocomplexes in RLU/mg protein in cell lines: 
(A) HEK293, (B) Caco-2 and (C) MCF-7. Data represented as mean ± SD (n=3), * p<0.05, **p<0.01 
and ***p<0.001 were considered statistically significant as determined by the Tukey-Kramer test. 
 
4.5.4.4 Acridine Orange/Ethidium Bromide (AO/EB) apoptosis assay 
There is an array of detrimental effects which can be induced upon exposure to nanoparticles 
to cells which include mitochondrial damage, genotoxicity, oxidative stress, radical 
production, glutathione depletion, lipid peroxidation, protein oxidation and apoptosis 
(Ramakrishna and Rao, 2011). Apoptosis is a programmed cell death that is genetically 
regulated to control the development of tissues by eliminating physiologically defective, 
damaged and abnormal cells (Liu et al., 2015) and is, hence, an effective defence mechanism 
of the body in eliminating tumour cells. The balance between cell proliferation and apoptosis 
is maintained in normal cells. However, cancer cells have been known to inhibit these 
pathways, thus ensuring their uncontrolled proliferation (Lodish et al., 2000). Apoptosis 
induces a number of morphological changes which are used for characterization purposes. 
These include cell shrinkage, condensed chromatin, formation of cytoplasmic protrusions and 
fragmentation of DNA (Abou-Ghali and Stiban, 2015). The cell membrane protrusions 
eventually separate from the cells to form apoptotic bodies. In contrast, necrosis results from 
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physical and chemical injury wherein cells die slowly by the progression of swelling and 
rupturing (Elmore, 2007).  
The AO/EB dual staining method is a useful technique to distinguish and characterise 
apoptotic cells based on morphology, colour of fluorescence emission and organization of 
chromatin condensation (Ciniglia et al., 2010). Acridine orange acts by permeating living 
cells and causing them to fluoresce green while cells which have lost their cytoplasmic 
membrane integrity selectively take up the EtBr stain as well as initiating the nucleus to 
fluoresce red (Liu et al., 2015). The nucleus of live cells will fluoresce green, apoptotic cells 
which has fragmented chromatin fluoresce red and necrotic cells orange (Ribble et al., 2005). 
All control cells fluoresced green, indicating the absence of apoptosis and necrosis (Figure 
4.12). The number of apoptotic cells after treatment with the PLL-AuNP:Fluc-mRNA 
complex was far greater than that of the PLL:Fluc-mRNAcomplex, indicating the ability of 
the PLL-AuNP:Fluc-mRNA to induce apoptosis. The distinct morphological characteristics 
of red apoptotic cells (‘A”) [which included cellular shrinking and blebbing (Figure 4.12), 
and orange necrotic cells (‘N’) which showed swelling (Figure 4.12)] were seen.  
The apoptotic index (Table 4.5) for the PLL:Fluc-mRNA complex was lower than that for the 
PLL-AuNP:Fluc-mRNA complexes in all cell lines correlating to the fluorescent intensity 
(Figure 4.13) measurements. PLL and its complexes has been proven to cause stress-induced 
apoptosis by mitochondrial permeabilization which has been proved by the detection of the 
activation of pro-apoptotic Bax channels forming protein cytochrome C release, activation of 
executioner caspases and alterations of membrane potential in the mitochondria of 
endothelial and hepatocyte-like cells (Symonds et al., 2005). AuNPs, by themselves, facilitate 
apoptosis by inducing morphological changes, loss of membrane potential and the production 
of reactive oxygen species in mitochondria (Kodiha et al., 2015). Hence, functionalisation of 
AuNPs with PLL combined their apoptosis-inducing effects, resulting in a greater apoptotic 
index compared to PLL on its own.  
The greater apoptotic index for the PLL-AuNP:Fluc-mRNA complex further indicates a 
normal cellular apoptosis defence mechanism which may be correlated to their excellent 
transfection efficiency and cytotoxicity. It has previously been reported that an increase in 
size, concentration and exposure time of cells to AuNPs results in a higher percentage of cells 
undergoing apoptosis (Mironava et al., 2010). It has been reported that concentrations of 
AuNPs up to 200 µg/ml exposed to MCF-7 cells displayed concentration-dependent 
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cytotoxicity through apoptosis detected by the upregulatated mRNA expression of p53, bax, 
caspase-3 and caspase-9 whereas the expression of anti-apoptotic bcl-2 mRNA was down-
regulated (Selim and Hendi, 2012).  Additionally, AuNPs show cell-type specificity for the 
induction of apoptosis as seen between the HEK293, Caco-2 and MCF-7 cell lines with the 
highest apoptotic index values seen in the Caco-2 cell line. 
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Figure 4.12: Fluorescence images obtained for the AO/EB apoptosis assay on HEK293, Caco-2 and 








Table 4.5. Apoptotic index values for each nanocomplex in the three cell lines.  
 
 
Figure 4.13: Fluorescence intensity (FI) in cell lines HEK293, Caco-2 and MCF-7 with and without 
treatment of the complexes. Data represented as mean ± SD (n=3). 
 
4.6 Conclusion 
The design and successful synthesis of PLL functionalised AuNP-based gene carriers have 
been shown to significantly influence transgene expression in the three cell lines tested. Gel 
retardation and florescence-based dye displacement assays demonstrated that these 
nanocomplexes were able to efficiently bind and condense Fluc-mRNA at low 
concentrations. The small size excellent colloidal stability and “flower-like” morphology of 
the nanocomplexes resulted in a highly compact structure capable of efficiently protecting the 
mRNA against nucleases, facilitated safe delivery of the cargo with low cytotoxicity and 
Cell line Sample Number of 
apoptotic cells 
Total number 













 2. PLL-AuNP:Fluc-mRNA 9 68 0.132 
Caco-2 1. PLL:Fluc-mRNA 12 62 0.194 
 2. PLL-AuNP:Fluc-mRNA 21 44 0.477 
MCF-7 1. PLL:Fluc-mRNA 5 31 0.161 
 2. PLL-AuNP:Fluc-mRNA 11 26 0.423 
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significant reporter gene expression. Furthermore, these nanocomplexes were able to induce 
apoptosis more so in the cancer cell lines (Caco-2 and MCF-7) than in the normal HEK293 
cell line, indicating their potential as anti-tumour agents. These results indicate that these 
PLL-AuNPs have the potential to be effective gene delivery vectors, especially for cancer 
therapy. Since cytotoxicity, transfection efficiency and apoptosis induction are highly 
dependent on the formulation characteristics of the nanoparticles, a factor that will have to be 
seriously considered in future studies. It is recommended that formulations of the PLL-
AuNPs of various concentrations, sizes, shapes and surface charges be prepared. 
Furthermore, studies of different environmental parameters such as exposure time and pH 
levels for the optimization of protocols could be critical in addition to assessing their 
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The use of non-viral gene carriers for the treatment of heterogenous diseases such as cancer is 
an exponentially growing field. Despite significant efforts made towards the development of 
these carriers, their biological safety, stability and delivery efficiency are limited. Hence, the 
need for novel gene delivery strategies that will overcome the challenges faced by current 
systems. Gold nanoparticles (AuNPs) have been applied in diagnostic and photothermal 
treatment of cancer, showing great promise as a gene delivery vehicle as they provide multi-
functional platforms for the delivery of a variety of therapeutic biomolecules. In addition, 
AuNPs are biocompatible, allowing for surface modification of cationic polymers which 
ensure electrostatic binding of nucleic acids without compromising their function, cellular 
uptake and release of the therapeutic cargo through endocytotic mechanisms. This study, 
investigated the delivery of mRNAs as opposed to the conventional pDNA since mRNA 
molecules have been reported as being more advantageous in terms of safety and their ability 
to overcome intracellular barriers. This study encompassed the development of chitosan (CS) 
and poly-l-lysine (PLL) functionalised AuNPs to effect electrostatic binding of mRNA 
molecules (Fluc-mRNA) and to investigate gene delivery and transgene expression in three 
mammalian cell lines. The outcomes of this study clearly indicate the potential of these 
delivery systems for future use in genetic vaccination and immunotherapy of cancer. 
Overall, AuNPs were successfully synthesized and functionalised with CS and PLL. 
Morphologically, the AuNPs appeared disperse, homogenous, spherical and formed 
agglomerates upon functionalization. All nanoparticle and nanocomplexes were less than 100 
nm in size, ensuring efficient cellular uptake. Furthermore, zeta potential analysis indicated 
the high colloidal stability of the AuNPs after functionalisation, attributing to their efficient 
cellular uptake and intracellular processing. Gel retardation and dye displacement assays, 
confirmed the good binding and compacting of the mRNA by the nanoparticles. Furthermore, 
the nanocomplexes did not lose their integrity after being subjected to nuclease digestion.  
In vitro cytotoxicity studies indicated that the functionalized nanocomplexes were relatively 
non-toxic and well tolerated in all three cell lines. Furthermore, they were able to elicit 
significant transgene expression in the three cell lines tested with highest expression recorded 
in the Caco-2 cell line.   
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These functionalised nanocomplexes were able to induce greater apoptosis in the cancer cell 
lines (Caco-2 and MCF-7) than in the normal HEK293 cell line, confirming their cell 
specificity. Overall, the functionalised nanocomplexes proved to be more stable, less toxic 
and more efficient than the individual cationic polymer:mRNA complexes, indicating that 
AuNPs functionalisation with CS and PLL enhanced the properties and biological functions 
of the nanocomplexes. Hence, these CS/PLL-AuNPs have the potential to be effective gene 
delivery systems especially for cancer treatment and results obtained thus far augur well for 
their use in future in vivo studies.   
Overall, the aims and objectives of this study were successfully achieved. However, further 
optimizations need to be considered before these nanocomplexes can be translated into 
clinical applications. There are several possible recommendations that can be addressed in 
future studies in this area. 
 
5.1  Future recommendations 
 To fully investigate the functionalisation of AuNPs with other CPs at different CP 
molecular weights and in different ratio formulations. 
 To improve the pharmacokinetics of the nanocomplexes by grafting with the steric 
stabilizing polymer, polyethylenegycol (PEG) or other suitable ligands.  
 Cytotoxicity and transfection studies revealed that the CP-AuNPs exhibited dose-
dependent and cell-type specific effects, indicating the requirement for broader 
concentration ranges and more cell types to be tested.  
 In depth studies of the fate of the nanoparticles, their mechanisms of cellular uptake, 
bio-distribution and biodegradability should be undertaken. 
 Since these nanocomplexes showed cell specificity with respect to transfection 
















APPENDIX A2: FTIR spectra 
 
        
      







APPENDIX B: NTA results 
 
 


























APPENDIX C: Conference Presentation 
 
Certificate of attendance for the 25th South African Society of Biochemistry and Molecular 




First place poster prize  in biotechnology awarded at the 25th SASBMB congress, East 
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